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Validation and Application of a Novel Target-Based Whole-Cell Screen to Identify
Antifungal Compounds
Abstract
Traditional approaches to drug discovery are inefficient and have several key limitations that constrain our
capacity to rapidly identify and develop novel experimental therapeutics. To address this, we have devised
a second-generation target-based whole-cell screening assay based on the principles of competitive
fitness, which can rapidly identify target-specific and physiologically-active compounds. Briefly, strains
expressing high, intermediate, and low levels of a preselected target protein were constructed, tagged
with spectrally distinct fluorescent proteins (FPs), and mixed together. The pooled strains were then
grown in the presence of various small molecules, and the relative growth of each strain within the mixed
culture was compared by measuring the intensity of the corresponding FP tags. Chemically-induced
population shifts indicated that the bioactivity of a small molecule was dependent upon the target
protein’s abundance and thus established a functional interaction. Here, we described the molecular tools
required to apply this technique in the prevalent human fungal pathogen Candida albicans and validated
this approach using dihydrofolate reductase. However, our approach, which we have termed target
abundance-based fitness screening (TAFiS), should be applicable to an extensive array of molecular
targets and in any genetically tractable microbe.
While the folate biosynthetic pathway has provided a rich source of antibacterial, antiprotozoal, and
anticancer therapies, it has not yet been exploited to develop uniquely antifungal agents. Although there
have been attempts to develop fungal-specific inhibitors of dihydrofolate reductase, the protein itself has
not been unequivocally validated as essential for fungal growth or virulence. The purpose of this study
was to establish dihydrofolate reductase as a valid antifungal target. Using a strain with doxycyclinerepressible transcription of DFR1 (PTETO-DFR1), we were able to demonstrate that Dfr1p is essential for
growth in vitro. Furthermore, nutritional supplements of most forms of folate are not sufficient to restore
growth when DFR1 expression is suppressed, or when its activity is directly inhibited by methotrexate,
indicating that Candida albicans has a limited capacity to acquire or utilize exogenous sources of folate.
Finally, the PTETO-DFR1 strain was rendered avirulent in a mouse model of disseminated candidiasis
upon doxycycline treatment. Collectively, these results confirm the validity of targeting dihydrofolate
reductase, and by inference other enzymes in the folate biosynthetic pathway as a strategy to devise new
and efficacious therapies to combat life-threatening invasive fungal infections.
Both the fungal fatty acid synthase and desaturase have been established as essential for fungal growth,
virulence in a systemic infection, and are structurally distinct from their mammalian counterparts.
However, there has been little success in developing clinically relevant inhibitors that target the fungal
fatty acid biosynthetic pathway, even though there are agents that inhibit the bacterial orthologs. The
purpose of this study was to identify physiologically-active compounds that interact with the fungal fatty
acid biosynthetic pathway. Given the challenging nature of targeting these enzymes using traditional
approaches, we attempted to apply the newly validated TAFiS method, a target-based whole-cell screen.
To accomplish this, Candida albicans strains with altered expression of the fungal fatty acid synthase or
the desaturase were used to screen a total of 41,261 small molecules. The primary hits were confirmed
through dose responses, and 16 compounds had differential activity on the strains with altered
desaturase abundance, indicating a functional chemical-target interaction. Additionally, the growth
inhibition exerted by the most potent hits was restored in the presence of exogenous fatty acids, further
supporting their inhibition of the fatty acid desaturase. Of the 16 confirmed hits, 11 were structurally
related, containing a hydrazide core that was essential for interaction with the desaturase. Collectively,
these results have identified a novel scaffold that interacts with the fungal fatty acid desaturase and can
be further developed into experimental therapeutics. It also confirms that the TAFiS methodology is highly

effective in identifying small molecules that functionally interact with targets that are poorly suited to
traditional chemical screening approaches.
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ABSTRACT

Traditional approaches to drug discovery are inefficient and have several key
limitations that constrain our capacity to rapidly identify and develop novel experimental
therapeutics. To address this, we have devised a second-generation target-based wholecell screening assay based on the principles of competitive fitness, which can rapidly
identify target-specific and physiologically-active compounds. Briefly, strains expressing
high, intermediate, and low levels of a preselected target protein were constructed, tagged
with spectrally distinct fluorescent proteins (FPs), and mixed together. The pooled strains
were then grown in the presence of various small molecules, and the relative growth of
each strain within the mixed culture was compared by measuring the intensity of the
corresponding FP tags. Chemically-induced population shifts indicated that the
bioactivity of a small molecule was dependent upon the target protein’s abundance and
thus established a functional interaction. Here, we described the molecular tools required
to apply this technique in the prevalent human fungal pathogen Candida albicans and
validated this approach using dihydrofolate reductase. However, our approach, which we
have termed target abundance-based fitness screening (TAFiS), should be applicable to
an extensive array of molecular targets and in any genetically tractable microbe.
While the folate biosynthetic pathway has provided a rich source of antibacterial,
antiprotozoal, and anticancer therapies, it has not yet been exploited to develop uniquely
antifungal agents. Although there have been attempts to develop fungal-specific
inhibitors of dihydrofolate reductase, the protein itself has not been unequivocally
validated as essential for fungal growth or virulence. The purpose of this study was to
establish dihydrofolate reductase as a valid antifungal target. Using a strain with
doxycycline-repressible transcription of DFR1 (PTETO-DFR1), we were able to
demonstrate that Dfr1p is essential for growth in vitro. Furthermore, nutritional
supplements of most forms of folate are not sufficient to restore growth when DFR1
expression is suppressed, or when its activity is directly inhibited by methotrexate,
indicating that Candida albicans has a limited capacity to acquire or utilize exogenous
sources of folate. Finally, the PTETO-DFR1 strain was rendered avirulent in a mouse
model of disseminated candidiasis upon doxycycline treatment. Collectively, these results
confirm the validity of targeting dihydrofolate reductase, and by inference other enzymes
in the folate biosynthetic pathway as a strategy to devise new and efficacious therapies to
combat life-threatening invasive fungal infections.
Both the fungal fatty acid synthase and desaturase have been established as
essential for fungal growth, virulence in a systemic infection, and are structurally distinct
from their mammalian counterparts. However, there has been little success in developing
clinically relevant inhibitors that target the fungal fatty acid biosynthetic pathway, even
though there are agents that inhibit the bacterial orthologs. The purpose of this study was
to identify physiologically-active compounds that interact with the fungal fatty acid
biosynthetic pathway. Given the challenging nature of targeting these enzymes using
traditional approaches, we attempted to apply the newly validated TAFiS method, a
target-based whole-cell screen. To accomplish this, Candida albicans strains with altered
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expression of the fungal fatty acid synthase or the desaturase were used to screen a total
of 41,261 small molecules. The primary hits were confirmed through dose responses, and
16 compounds had differential activity on the strains with altered desaturase abundance,
indicating a functional chemical-target interaction. Additionally, the growth inhibition
exerted by the most potent hits was restored in the presence of exogenous fatty acids,
further supporting their inhibition of the fatty acid desaturase. Of the 16 confirmed hits,
11 were structurally related, containing a hydrazide core that was essential for interaction
with the desaturase. Collectively, these results have identified a novel scaffold that
interacts with the fungal fatty acid desaturase and can be further developed into
experimental therapeutics. It also confirms that the TAFiS methodology is highly
effective in identifying small molecules that functionally interact with targets that are
poorly suited to traditional chemical screening approaches.
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CHAPTER 1.

INVASIVE FUNGAL INFECTIONS AND THE NEED FOR NEW
ANTIFUNGALS

Fungal Infections Are a Significant Cause of Human Morbidity and Mortality
Superficial infections of the skin, hair, or nails are estimated to affect 1.7 billion
individuals annually [1]. Millions more suffer from mucosal fungal infections of the oral
and reproductive tracts [2-4]. Both superficial and mucosal diseases severely impact the
individual’s quality of life, however neither infection is typically life-threatening. In
contrast, the dissemination of fungal pathogens into the bloodstream, or invasive fungal
infections (IFIs), are estimated to affect 3 million people each year globally, with
mortality rates surpassing 50% [1], despite appropriate antifungal treatment. The majority
of IFIs can be attributed to species of the Aspergillus, Pneumocystis, Candida, and
Cryptococcus genera [1]. Aspergillus species are estimated to account for more than
200,000 IFIs per year, with mortality rates ranging from 30-95% [1], primarily caused by
Aspergillus fumigatus, a ubiquitous mold. Likewise, Pneumocystis species are
responsible for over 400,000 IFIs annually, with mortality rates of 20-80% [1], and the
widespread atypical fungus Pneumocystis jirovecii is the leading cause of these IFIs.
Another 1,000,000 IFIs annually are attributed to species of Cryptococcus, typically the
ubiquitous yeast Cryptococcus neoformans, with mortality rates of 20-70% [1]. Finally,
another 400,000 IFIs per year are due to Candida species with mortality rates ranging
from 46-75% [1].
Candida spp. are the second leading cause of catheter-associated urinary tract
infections, the third leading cause of central line-associated bloodstream infections, the
third-highest cause of bloodstream infections in the intensive care unit, and are the fourth
leading cause of nosocomial bloodstream infections [5-8]. In the U.S. alone, 25,000 new
cases of disseminated candidiasis are reported annually [9] with an estimated health care
cost of up to $4 billion a year [10], and increased hospital length of stay by 10-21 days
[11]. C. albicans causes the majority of all bloodstream Candida infections globally [1216] with mortality rates that range 29-72% [5, 17, 18], although other non-albicans
Candida species are increasing in incidence [19, 20]. In addition to IFIs, the overgrowth
of Candida species can cause superficial, and mucosal infections. Superficial Candida
infections can affect otherwise healthy individuals and are typically in warm, humid folds
of adjacent skin where the primary anatomical barrier has been damaged [21]. Mucosal
infections can manifest as either oropharyngeal candidiasis (OPC) or vulvovaginal
candidiasis (VVC). OPC is estimated to afflict nearly every HIV/AIDS patient [22], and
is often associated with oral cancers [23, 24]. While OPC is not life-threatening, it does
pose serious quality of life problems including nutrient acquisition in adults and failure to
thrive in infants [22]. VVC is estimated to impact 70-75% of women in their childbearing years, regardless of immunocompetency, with up to 10% of women developing
recurrent infections defined as more than four episodes a year [2, 4]. VVC, and especially
recurrent vulvovaginal candidiasis, have substantial negative impacts on both
occupational and social behaviors [25].
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In a healthy individual, the first line of defense against microbial infections is the
anatomical barriers composed of the skin and mucosa [10, 26]. The skin provides a
physical barricade against pathogens, while mucosal surfaces utilize acidic pH, mucus,
and antimicrobial secretions [22, 26] to prevent microbes from invading the body. The
second barrier to pathogenic microbes is the innate immune system. The innate response
includes the complement cascade, tissue-resident phagocytes, and antimicrobial peptides
[26]. The immunological barrier can be compromised in disease states such as
HIV/AIDS, or suppressed during antirejection or antineoplastic therapies leaving the
individual at risk for infection [1].
Increases in the number of patients whose normal barriers, either anatomical or
immunological, have been compromised is concerning as these are the most at risk for
fungal infections. The anatomic barriers are often disrupted during invasive surgery,
insertion of catheters, or injury [10, 12]. These disruptions allow the colonization of and
dissemination to sterile sites by fungi. The immune system is the second line of defense
against fungal infections but can be compromised by disease or medical intervention. The
on-going HIV and type-2 diabetes epidemics are major risk factors for mucosal fungal
infections [12, 22, 26], while immunosuppression for solid organ transplant or
antineoplastic therapy are major risk factors for invasive fungal infections (IFIs) [12, 14].
Additionally, the use of broad-spectrum antibiotics increases the risk of Candida
infections as they wipe out the native microflora allowing overgrowth of the fungi [14,
15, 21]. Improvements in medical and supportive care have and continue to expand the
population susceptible to fungal infections, further increasing the need for antifungal
agents.

Candida albicans Virulence Factors
C. albicans is native to the human microflora and an opportunistic pathogen as it
survives and causes disease in anatomically and environmentally distinct niches. C.
albicans is estimated to asymptomatically colonize the gastrointestinal tracts of nearly
60% of the human population [27], the reproductive tract of roughly 70% of the
population [2], and the oral mucosa of up to 80% [22]. This opportunistic pathogen’s
ability to occupy and infect such disparate environments is supported by a myriad of
virulence factors. The expression of adhesins enables C. albicans to attach to biotic and
abiotic surfaces, and are essential for both pathogenicity and biofilm formation [17, 28].
Once attached, C. albicans secretes hydrolytic enzymes, phospholipases and secreted
aspartyl proteases, that both facilitate the active invasion of host tissues and extract
nutrients from the extracellular environment [29]. C. albicans also secretes candidalysin,
the first fungal cytolytic peptide toxin, which directly damages host cells [30]. However,
C. albicans ability to reversibly switch morphology between the isotropic yeast form and
the filamentous hyphal and pseudohyphal forms is thought to indicate the transition from
a harmless commensal to a life-threatening pathogen [17]. In addition, morphological
transitions allow the expression of hyphal specific genes that promote virulence,
including adhesins and hydrolytic proteins, indicating that morphology switching is key
to C. albicans pathogenicity.
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The Inadequacy of Current Antifungal Therapies
Current antifungal therapies are woefully inadequate to combat life-threatening
infections as the unacceptably high mortality rates occur even with the appropriate use of
the three antifungal drug classes [31-38]. Treatment of IFIs is severely limited by the
significant restrictions of these therapies, including rising fungal resistance, patient
toxicity, or a narrow spectrum of activity [31-38]. Azoles are the most widely used class
of antifungals due to broad-spectrum activity and relatively low patient toxicity [39, 40].
This class inhibits lanosterol demethylase (Erg11p) in the ergosterol biosynthetic
pathway, depleting ergosterol and producing toxic sterol intermediates that inhibit fungal
growth [41]. Currently, only 0.5-2% of C. albicans bloodstream isolates are resistant to
fluconazole, the most commonly used azole, and only 7% of all Candida bloodstream
isolates are resistant [42]. However, resistance is rising, especially with the emergence of
inherently resistant species such as Candida auris [36]. Despite these low resistance
rates, between 19% and 46% of patients will not respond to treatment with the azoles,
even when the fungal isolate is determined to be susceptible according to current MIC50
breakpoints [43-48]. Worryingly, these treatment failures are not resistance-related, and
therefore indicate the only modest efficacy of these drugs. The emerging resistance and
clinical failures will soon limit the therapeutic value of this class.
A second antifungal class, the polyenes, contains only one drug that is approved
for systemic use, amphotericin B. Amphotericin B directly interacts with ergosterol in the
fungal membrane to induce stress and cell death. Previously, the drug was thought to
intercalate into the membrane to form pores, which cause the loss of membrane integrity
[49]. Recently, it was reported that the drug forms extramembrane aggregates that
remove ergosterol, thus destabilizing the plasma membrane [50]. Regardless of the
mechanism, amphotericin B has potent fungicidal activity with broad-spectrum activity,
making this drug a robust last line of therapy for complicated IFIs [40]. Amphotericin B
has a higher affinity for ergosterol than cholesterol driving fungal selectivity [40], but
there is still substantial patient toxicity, including nephrotoxicity and renal failure, which
were associated with substantial increases in morbidity and mortality [51]. Liposomal
formulations of amphotericin B were developed that reduce the adverse effects [51, 52].
Fortunately, clinical resistance to amphotericin B is rare [53]. However, up to 38% of
patients treated with amphotericin B will fail to respond to treatment [54, 55].
The third antifungal class, the echinocandins, are the most recently approved [56].
This class causes the loss of cell wall integrity by non-competitively inhibiting 1,3-β-Dglucan synthase (Fks1p), an enzyme that makes the essential cell wall component 1,3-βD-glucan [57-59]. The absence of a cell wall in mammalian cells limits patient toxicity
allowing the echinocandins to selectively target fungal cells. However, this class has a
narrow spectrum of activity, and is only available as intravenous formulations, limiting
their clinical utility [59]. Currently, resistance is low, but emerging as roughly 3% of
Candida glabrata isolates are resistant to the echinocandins, in addition to their inherent
resistance to fluconazole [42]. Furthermore, between 27% and 48% of patients treated
with the echinocandin, caspofungin, fail therapy [48, 54, 55, 60, 61]. Therefore, it is clear
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that current antifungal agents are inadequate to combat IFIs, and we have an urgent need
to develop new therapies that improve patient outcomes.

Antifungal Drug Discovery: Traditional Approaches and Challenges
The process of drug discovery, development, and approval is estimated to cost
$2.5 billion, and to take over a decade [62]. The preclinical phase is estimated at nearly
31% of the total cost and accounted for 50% of the timeline [62]. Thus, there is an urgent
need to increase the efficiency of discovering and developing novel therapeutics. This
need is especially crucial with antifungals, as the most recent drug class, the
echinocandins, took thirty years to reach patients [56]. This lengthy timeline and expense
is a direct result of the high attrition rate of promising drug candidates. Many failures are
due to conventional screening assays that identify primary hits lacking essential aspects
of effective therapies, including target specificity or membrane permeability. By
identifying compounds that lack drug-like properties, conventional approaches require
significant time and investment to identify the compounds that possess the appropriate
characteristics. This inadequacy is a direct result of the limitations of the two most
prevalent drug screening methodologies [63]. The first, target-based screens, require the
development of a biochemical assay to detect modulators of a purified target protein’s
activity. While this approach often yields potent inhibitors of the purified protein, many
of these hits lack activity on whole cells due to their insufficient membrane permeability
or an inability to engage the molecular target in its native environment [64]. This
necessitates costly efforts to improve cell permeability and/or selective target engagement
that are often unsuccessful [65]. In addition, target-based screens are not applicable to
many proteins, either because they are not amenable to purification or because the
enzymatic assay is not high-throughput (HTP) compatible. Therefore many hits from
target-based screens have not developed into clinical therapies [64], and a substantial
fraction of time and resources have been lost to poor quality hits.
The alternative approach is whole-cell, or phenotypic, screening which identifies
compounds that induce or correct disease-relevant phenotypes, such as inhibiting
microbial growth. While these screens identify compounds that are active on whole cells,
they do not provide information on the cellular target or the mechanism of action (MOA),
both of which have to be identified in prolonged and costly subsequent studies [66]. Thus
both of these screening strategies require substantial follow up in preclinical stages of
development to triage the significant fraction of compounds that are viable. Therefore,
the rapid identification of primary screening hits that exert physiological activity via a
defined molecular target, coupled with the elimination of compounds that lack targetspecificity and whole-cell activity, should substantially increase the efficiency of this
stage in drug discovery.
One of the major problems in antifungal drug discovery is that fungi are
eukaryotic and, therefore, fundamentally similar to the human host. The similarity of the
cellular signaling and biochemical pathways of the model fungus, Saccharomyces
cerevisiae, indicates that these are highly conserved [67]. This conservation between
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fungi and humans dramatically reduces the number of available drug targets that can be
successfully and safely exploited to derive antimicrobial molecules with fungal selective
toxicity. Indeed, two of the three antifungal classes target ergosterol, a fungal specific
sterol, and the third targets the cell wall, which is entirely absent in humans. In theory,
fungal selective inhibitors are more likely to become clinical therapies, as human toxicity
is a major reason for clinical trial failure [68, 69]. Therefore conventional drug
discovery’s inefficiency and the fundamental similarity of fungal pathogens to the human
host further hinders the development of selective antifungal agents that exploit novel
targets.

Target-Based Whole-Cell Screens Greatly Improve the Efficiency of Drug Screening
A massive improvement in the efficiency of drug screening came from combining
both of the conventional approaches in the form of Target-Based Whole-Cell Screens
(TBWCS). These approaches rely on the principle of chemical genetics [70], where the
abundance of the target protein determines the susceptibility to an on-target inhibitor.
Therefore a strain with decreased target abundance would be hyper-susceptible to an ontarget inhibitor. Early TBWCS compared the growth between two strains, a reference
strain and one that has decreased target protein abundance [71]. Primary screening hits
were identified as those that affected the growth of the knockdown strain more than the
growth of the reference strain. This differential growth inhibition indicates a functional
interaction between the compound and the target of interest. Several studies with
Staphylococcus aureus and Mycobacterium tuberculosis have collectively established the
validity of TBWCS assays to discover on-target chemical probes [71-73].
TBWCS have many benefits over both of the traditional approaches. First, only
compounds that interact with a predefined target of interest are identified, providing
information on the target and MOA, from the primary screen. Second, only molecules
that interact with the target in its native context, i.e. in intact cells, are selected,
eliminating compounds with poor membrane permeability, those that fail to engage the
intended target, or those that have substantial off-target effects. Third, by comparing the
growth between two strains, this approach does not require the purification of the target
or a high throughput (HTP) compatible biochemical assay for the primary screen.
Therefore, this approach can be applied to targets that are traditionally challenging, such
as non-catalytic proteins or those that are not amenable to purification. Thus, TBWCS
have the potential to expedite the identification of a diverse physiologically active
collection of agents that interact with a defined molecular target and eliminate
compounds that have substantial off-target effects or are generally toxic.
Even with these advantages, TBWCS are underutilized and can be improved.
Each of the previous efforts have been restricted by several technical issues that have
limited efficiency, sensitivity, and/or throughput of the approach. First, previous TBWCS
only utilized two strains to screen chemical libraries, a reference and a knockdown strain.
The sensitivity of the assay is still limited as highly potent on-target compounds can
overwhelm the dynamic range of the assay and have the same effect on both strains.
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Second, previous screens used two plate assays that compare the growth of reference and
knockdown strains on separate culture plates, limiting the efficiency and throughput of
the assay. Finally, most of the previous TBWCS relied on a semi-quantitative output,
such as zones of growth inhibition, which are not designed for quantitative
measurements, automated data collection, or statistical analysis [71, 74].

Hypothesis and Objective
The overall goal of this work is to validate a new methodology that will improve
the efficiency, sensitivity, and throughput of drug screening as well as lay the
groundwork to exploit three new drug targets for antifungal development. We
hypothesize that our TAFiS methodology will increase the efficiency and throughput of
TBWCS, and identify chemical modulators for conventionally challenging targets. The
advantages of the TAFiS assay will save both time and money in the early stages of drug
discovery, providing faster and more cost-effective novel antifungal therapies. To test
this hypothesis we will apply and validate this methodology using a target from the wellcharacterized, and historically important folate pathway, but has not been validated in
fungi. We will also apply our methodology to less characterized, more challenging targets
in the fungal fatty acid synthesis pathway.

Validation of dihydrofolate reductase as an antifungal target
The folate (FOL) biosynthetic pathway has been successfully targeted in the
development of antineoplastic, antibacterial, and antiprotozoal drugs. In this pathway,
GTP is converted to dihydroneopterin triphosphate by GTP cyclohydolase I (Fol2p), and
then subsequently condensed with PABA to form dihydropteroate by the subsequent
actions of dihydroneopterin aldolase (DHNA), hydroxymethyldihydropterin
pyrophosphokinase (HPPK) and dihydropteroate synthase (DHPS). In yeast the DHNA,
HPPK, and DHPS are provided on a single trifunctional protein (Fol1p). Then
dihydrofolate synthase (DHFS, Fol3p) adds a single L-glutamate residue to produce
dihydrofolate, which is then reduced by dihydrofolate reductase (DHFR) to
tetrahydrofolate. Notably, humans lack four of the enzymes required to produce folate,
DHNA, HPPK, DHPS, and DHFS. Antineoplastics include FOL analogs such as
methotrexate (MTX), a potent nonselective inhibitor of DHFR [75, 76]. Other notable
antifolates include trimethoprim, a bacterial DHFR inhibitor, and a collection of ‘sulfa
drugs’ including sulfamethoxazole that inhibit DHPS from bacterial and protozoan
species [77]. DHFR inhibitors pyrimethamine, proguanil, chlorproguanil have been
crucial to treat malaria [78-80], as well as the DHPS inhibitor dapsone [81]. A
combination of trimethoprim and sulfamethoxazole can also provide an effective
treatment for Pneumocystis pneumonia caused by the atypical fungus Pneumocystis
jirovecii [82]. Although these drugs were not specifically developed to target the fungal
folate biosynthetic enzymes of Pneumocystis, this provides clinical evidence that
inhibition of the FOL pathway can provide an effective intervention strategy to treat
invasive mycoses. However, conventional antifolate drugs that were developed for
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bacterial, protozoan, human FOL enzymes have little or no activity upon the major
human fungal pathogens [83-85]. This lack of activity is either because of divergence of
the fungal enzyme structures, or the inability of antifolates to enter fungal cells [83].
Furthermore, no published study has unequivocally validated the core components of the
FOL pathway as essential for infectious fungi to cause disease within a mammalian host,
and are therefore genuine and potentially efficacious targets for antifungal development.
We hypothesize that the fungal DHFR is required by C. albicans to survive in vitro, and
cause disease in vivo.

Establish a novel target-based whole-cell screen
Traditional drug screening approaches are inefficient and have several key
limitations that hinder our capacity to identify and develop novel therapeutics. To address
this, we have designed a second-generation TBWCS, called Target Abundance-based
Fitness Screening (TAFiS) that incorporates the principle of competitive fitness, and
should rapidly identify target-specific and physiologically active agents. Our approach
increases the number of strains with altered target abundance compared to previous
TBWCS, which produces more data points per compound, and increases the dynamic
range of the assay by including strains with enhanced stratification of the target protein
abundance. Additionally, all strains will be combined into a single population for
screening, forcing the strains to compete with each other in the presence of screening
compounds. By incorporating the principle of competitive fitness, the sensitivity of the
assay should increase, as even minute fitness defects caused by the screening compound
will become apparent in the competition between strains. Combining the strains together
will also allow the screen to be conducted in a single plate, increasing the efficiency
when compared to the two-plate assays previously employed. Finally, our approach
enables the quantification of each strain’s growth using fluorescence to facilitate rapid
measurement and statistical analysis. This methodology could be universally applied to
any potential drug-target in any genetically tractable microbe. We hypothesize that this
methodology will increase the sensitivity and efficiency of drug screening by rapidly
identifying primary screening hits with activity on intact cells that act through a defined
molecular target and eliminate compounds that lack the desired characteristics of
promising antifungal lead compounds. The purpose of this study was to validate the
TAFiS methodology as a novel TBWCS approach to drug screening by generating the
fluorescent protein constructs, the tools to alter the target abundance, and to ensure that
screen identified known on-target inhibitors using lanosterol demethylase, target of the
azoles, and DHFR.

Utilizing TAFiS to identify inhibitors of the fungal fatty acid biosynthetic pathway
Next, we applied our new TBWCS approach to identify inhibitors of fungal fatty
acid synthesis. Fatty acids are vital constituents of membrane lipids, an important means
to store metabolic energy, and are required for post-translational modifications of many
essential proteins. There have been very few efforts to exploit this pathway in infectious
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fungi, even though the same biological processes have been successfully targeted in
bacteria [86, 87]. The proteins in this pathway are conventionally difficult drug-targets as
they are not amenable to purification and do not have HTP compatible biochemical assay.
We hypothesize that the TAFiS methodology could identify novel inhibitors of two
traditionally challenging targets: the fungal fatty acid desaturase (Ole1p) and the fungal
fatty acid synthase (FAS). We propose to develop strains that have an altered abundance
of either FAS or Ole1p and then to identify novel inhibitors by screening chemical
libraries using the TAFiS methodology.

Structure-activity relationship of a known fatty acid desaturase inhibitor
Finally, we determined the structure-activity relationship of a previously
identified family of molecules with a 1,2,4-triazolidine-3-thione core that interacts with
Ole1p [88]. Upon investigation, we noticed that one of the molecules had the potential to
degrade into a remarkably similar hydrazone molecule to a previously published series of
molecules with potent antifungal activity but no known target [89, 90]. We synthesized
the original molecule and found that the 1,2,4-triazolidine-3-thione molecule degraded
into the predicted hydrazone product. This observation led us to investigate the aspects of
the molecule’s structure that determined the activity. We hypothesize that identifying the
structural elements that drive this Ole1p inhibitor might help the development of future
inhibitors and improvements upon this scaffold.
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CHAPTER 2. DIHYDROFOLATE REDUCTASE IS A VALID TARGET FOR
ANTIFUNGAL DEVELOPMENT IN THE HUMAN PATHOGEN CANDIDA
ALBICANS1

Introduction
The CDC estimates that the direct healthcare costs of treating fungal infections to
be over $7 billion each year in the U.S. alone [91]. Along with this high financial burden,
over 1 million deaths are attributed to invasive fungal infections (IFIs) annually [1],
despite the appropriate use of the available antifungal drugs. The most widely used
antifungal drug class, the azoles, inhibit ergosterol biosynthesis, but the incidence of
resistance is on the rise and starting to compromise their clinical utility [42]. The polyene
amphotericin B disrupts fungal membranes through direct interaction with ergosterol
[92]. However, despite broad-spectrum antifungal activity, this drug is associated with
severe patient toxicity that limits its use. The most recently approved antifungal drugs are
the echinocandins, which target cell wall biosynthesis. Drugs in this class are principally
active against Candida species, and therefore have a narrow spectrum of activity and are
only available in intravenous formulations, further limiting their clinical utility [38]. A
larger concern is the modest efficacy of all three classes of antifungal drug, as this is
likely a major determinant of the excessively high mortality rates in patients with IFIs, as
well as the high rates of recurrent mucosal infections. For example, approximately a third
of patients with disseminated Candida infections are non-responsive to treatment with
fluconazole [43, 44, 46, 93, 94], voriconazole [47], or the recently approved
isavuconazole [48], even among those infected by isolates deemed susceptible according
to current clinical breakpoints. Favorable response rates of just 52 to 73% have been
reported for patients with disseminated candidiasis when treated with an echinocandin
[48, 54, 55, 60, 61] and 62% with amphotericin B [54, 55]. Of grave concern is the recent
isolation of C. auris from patients across the globe that is resistant to all three classes of
antifungal drugs [36]. As such, there is an urgent need for new antifungal drugs with
improved therapeutic efficacy, patient safety, and spectrum of activity.
In its reduced form, tetrahydrofolate (THF), folate is an essential coenzyme for a
number of cellular enzymes, serving as a carrier for the transfer of one-carbon units as
well as their interconversion between various oxidation states [95]. THF is required for
the synthesis of thymidine monophosphate, purines, methionine, as well as a multitude of
other important metabolites. Mammals are unable to synthesize folate as they lack several
of the necessary enzymes and must acquire it through dietary intake. A specialized
transport system is required for cellular uptake of folic acid, which is then converted into
its active form, THF, by dihydrofolate reductase (DHFR) [96]. In contrast, the majority
of prokaryotes and microbial eukaryotes lack the transport systems found in mammals
and must therefore synthesize folic acid de novo.

1

Reprinted from final submission with open access permission. DeJarnette C, Luna-Tapia A, Estredge LR,
Palmer GE. 2020. Dihydrofolate reductase is a valid target for antifungal development in the human
pathogen Candida albicans. mSphere 5:e00374-20. https://doi.org/10.1128/mSphere.00374-20. [97]
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The folate biosynthetic pathway has been targeted with enormous success in the
development of antineoplastic, antibacterial, as well as antiprotozoal drugs. Anticancer
drugs include folate analogs such as methotrexate (MTX), a potent inhibitor of DHFR
[75, 76]. Other notable antifolates include trimethoprim, which inhibits bacterial DHFR,
and a collection of sulfa drugs including sulfamethoxazole that inhibit dihydropteroate
synthase (DHPS) from some bacterial as well as protozoan parasites [77]. Antiprotozoal
drugs that target this pathway have been especially important for the treatment of malaria
and include the DHFR inhibitors pyrimethamine, proguanil, chlorproguanil [78-80], as
well as the DHPS inhibitor dapsone [81]. Curiously, a combination of trimethoprim and
sulfamethoxazole can also provide an effective treatment for Pneumocystis pneumonia
caused by the atypical fungus Pneumocystis jirovecii [82]. Although these drugs were not
specifically developed to target the folate biosynthetic enzymes of Pneumocystis, this
provides clinical evidence that targeted inhibition of the folate (FOL) pathway can
provide an effective intervention strategy to treat invasive mycoses. However, the
conventional antifolate drugs developed for bacterial or protozoan DHPS or DHFR, or
even to human DHFR, have little or no antifungal activity upon the major human fungal
pathogens [83-85], either because of divergence of the fungal enzyme structures or
permeability issues that prevent antifolates from entering fungal cells [83]. Furthermore,
until now, no published study has unequivocally determined if the core components of
the FOL pathway are required by infectious fungi to cause disease within a mammalian
host, and are therefore valid and potentially efficacious targets for antifungal
development. The objective of this study was to determine if DHFR is essential for C.
albicans, one of the most prevalent human fungal pathogens, to survive and cause disease
within its mammalian host.

Materials and Methods

Growth conditions
C. albicans was routinely grown on yeast extract-peptone-dextrose (YPD) agar
plates at 30°C, supplemented with 50 μg/ml uridine for ura3 Δ/Δ strains. Selection of C.
albicans transformants was carried out on minimal YNB medium (6.75 g/liter yeast
nitrogen base without amino acids, 2% dextrose, 2% Bacto agar) supplemented with the
appropriate auxotrophic requirements described for S. cerevisiae [98] or with 50 μg/ml
uridine.

Candida albicans strain construction
BWP17 [99] was kindly provided by Aaron Mitchell (Carnegie Mellon
University). C. albicans was transformed with DNA constructs using the lithium acetate
procedure [100]. The parental strain, BACTR31, was constructed by transforming
BWP17 with pDUP3 [101] that contains the tetracycline repressor protein (TetR) from
Nakayama and colleagues [102]. To generate this plasmid, TetR from THE1 [102] was
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PCR amplified using primers TetRHap4ADF-SalI and TetRHap4ADR-MluI, and then
cloned into pDUP3 between Sal I and Mlu I sites. This pDUP3:TetR plasmid was
linearized using Nae I and transformed into BWP17.
The DFR1 gene deletion cassette was amplified using primer set DFR1DISF and
DFR1DISR and plasmid pRSARG4ΔSpeI (ARG4 selection marker) as a template and
transformed into BACTR31. Correct integration of the gene deletion cassette to replace
one DFR1 allele was confirmed by diagnostic PCR, using primers ARG4INTR2 and
DFR1AMPR-SacI as well as ARG4INTF2 and DFR1AMPF-KpnI. To make the PTETODFR1 strain, we generated promoter replacement cassettes by PCR amplifying the
tetracycline-repressible promoters from the plasmids p97CAU, p98CAU, or p99CAU
[101] using the primers DFR1TETF and DFR1TETR. Each cassette was transformed into
the BACTR31 derived DFR1/dfr1Δ:ARG4 heterozygote, and the presence of the PTETO
was determined by diagnostic PCR using TETOSEQF and DFR1DETR. The absence of a
wild-type allele was determined by diagnostic PCR using DFR1AMPF-KpnI and
DFR1DETR. The strains were then made prototrophic by transforming pGEMHIS1 [103]
linearized with Nru I. Oligonucleotides used in this study are listed in Table 2-1.

RNA isolation and RTqPCR
RNA was isolated using the hot phenol method of RNA isolation described
previously [104]. This RNA pellet was washed with 500 μl of 70% ice-cold ethanol and
collected by centrifugation. The RNA pellet was resuspended in Dnase/Rnase-free
H2O. cDNA was synthesized from total RNA using the Verso cDNA Synthesis Kit
(Thermo Scientific) in accordance with the manufacturer’s instructions. Synthesized
cDNA was used for both the amplification of ACT1 and the gene of interest by PCR,
using SYBR green PCR master mix, according to the manufacturer’s instructions. Genespecific primers were designed using the PrimerQuest Tool from Integrated DNA
Technologies (IDT). The PCR conditions consisted of an initial denaturation at 95°C for
10 minutes, followed by 40 cycles of denaturation (95°C for 15 seconds), annealing
(60°C for 30 seconds), and extension (72°C for 37 seconds). Software for the 7500
System Sequence Detection Software version 1.2.3 from Applied Biosystems was used to
determine the dissociation curve and threshold cycle (CT). The 2−ΔΔ CT method was used
to calculate changes in gene expression among the strains [105]. All experiments
included both biological and technical replicates in triplicate.

Antifungal susceptibility testing
Stock solutions of MTX were prepared at 10 mM in DMSO and diluted as needed
in the same solvent. Each C. albicans strain was grown overnight in YPD at 30°C and
diluted to approximately 1 X 104 cells/ml in YNB or RPMI 1640 medium, and 100 μl of
each cell suspension was transferred to the wells of a round-bottom 96-well plate. An
additional 100 μl of YNB or RPMI 1640 medium containing 2x the final desired
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Table 2-1.

Oligonucleotides used in Chapter 2.

Primer
DFR1DISF
DFR1DISR

Sequence 5’ → 3’
TTCTTGTTTGATTGAAAAAAAACTTTCACCACTAATCTAGAACTT
CACGAATAGACAACAGTTTTCCCAGTCACGACGTT
TTATTTTCTTGTCCATAGCGTATAATTATAGGTAAAATCACCTTC
CTTGATATCGTCTTTGTGGAATTGTGAGCGGATA

DFR1TETOF

TGGACTTAGGGGTACTTGGCCAGGTATTGTATTTTTATCAGGTTA
TTCATTGTTGCACTCTAGGGTAATACGACTCACTATAGGG

DFR1TETOR

CTTTGTATCCAATTCCCAAAGCAGGCTTTAATGCCGCGACAATGA
TTGCAACATTTGGTTTCAGCATCTAGTTTTCTGAGATAAAGCTG

ARG4INTF2

AAGCTAGTGTGGAAAGAAGAG

ARG4INTR2

AATGACTGAATTATGTCGGTC

DFR1AMPFKpnI

TCAGGTACCTTGAGTTGTGGACTTAGTGGG

DFR1AMPRSacI

TCAGAGCTCCGACTTTGGAGAGAGAACAGC

TETODETF

GTTGACACTTGTAAATAAGCG

DFR1DETR

TTGGTCCAACTTTCCAATGGG

TetRHap4ADF- TCAGTCGACATGTCTAGATTAGATAAAAGTAAAG
Sal1
TetRHap4ADR
- Mlu1

TCAACGCGTCAACTCAATTGAGGTTACTCGG

DFR1q1

TGTTGCAATCATTGTCGCGG

DFR1q2

CCTTACGGAGTCTCCAAGGC

ACT1q1

TTGGATTCTGGTGATGGTGTTA

ACT1q2

TCAAGTCTCTACCAGCCAAATC

Engineered restriction enzyme sites are underlined.
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concentration of MTX was then added to each well. The final concentration of DMSO
was 0.5% for all treatments. Plates were then incubated at 30°C before growth was
quantified after 24 and 48 hours by measuring OD600nm using a Cytation 5 plate reader
(Bio-Tek Instruments, Inc.). MIC50 values were identified visually using the CLSI
antifungal susceptibility assay and then confirmed by quantifying growth by OD600nm.
The growth of each strain at each drug concentration was then expressed relative to the
DMSO-alone control. The susceptibility to MTX at the highest concentration in each pH
was compared to the other pH using a two-tailed student’s t test (* P < 0.01; ** P <
0.0001).

Mouse model of disseminated candidiasis
All animal experiments were done according to protocols approved by the
University of Tennessee Institutional Animal Care and Use Committee. Groups of 6 to 8week-old female BALB/c mice (Charles River Laboratories) were randomly assigned to
one of three treatment groups three days before infection. Group 1 (minus doxycycline)
was provided 20 g of DietGel (Clear H2O) per day, per cage of 4 mice, while group 2
(plus doxycycline) was provided the same diet supplemented with 2 mg/ml of
doxycycline hyclate. Group 3 (post-treatment) were given the DietGel without
doxycycline until 24 hours after infection and were administered 10 mg/kg of
doxycycline through oral gavage at 12, 24, and 36 hours post-infection. Treatment was
maintained daily for the duration of the experiment (up to 12 days post-infection). Each
C. albicans strain was grown overnight in YPD cultures at 30°C (200 rpm). Cells were
washed twice in sterile endotoxin-free phosphate-buffered saline (PBS), and cell density
determined using a hemocytometer. Each strain was then diluted to 5 X 106 cells/ml in
sterile PBS, and 0.1 ml of each cell suspension inoculated into the lateral tail vein of mice
from each treatment group. Viable cell counts of each inoculum were confirmed by
plating appropriate dilutions onto YPD agar plates and counting the number of colonies
formed after 48 hour. Mice were monitored for 12 days, and those showing distress
euthanized. Survival data were plotted on a Kaplan–Meier curve and analyzed by Logrank (Mantel-Cox) test using GraphPad Prism 8.00. The kidneys from each mouse were
extracted, weighed, and homogenized in PBS. Serial dilutions of kidney homogenate
were plated on YPD agar plates containing 50 μg/ml of chloramphenicol. The number of
CFU/gram of kidney tissue was determined from the number of colonies on the plates
after 48 hours.

Purification of the Candida albicans dihydrofolate reductase
The C. albicans DFR1 ORF sequence was retrieved from the Candida Genome
Database [106], and was codon optimized for expression in E. coli. The optimized DFR1
ORF was then cloned into pET15b [107] to allow propagation and expression of C.
albicans Dfr1p in E. coli. Cultures of E. coli transformed with pET15b: CaDfr1p
(Biomatik) were grown overnight in LB plus ampicillin. The culture was diluted 1:100
into fresh media and incubated at 35°C for 6 hours, then Dfr1p expression was induced
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with 0.5 mM IPTG final concentration for 16 hours. Cells were collected by
centrifugation and resuspended in binding buffer (6 g/l Tris base pH 7.5, 8.8 g/l NaCl, 1
mM DTT, 0.68 g/l imidazole, 5% glycerol, 1X protease inhibitor). Resuspended cells
were lysed with 1 mg/ml chicken white lysozyme (Sigma) for 60 min at 4°C. Then Triton
X 100 and NaCl were added to 0.1% and 0.5 M respectively. The lysate was then
centrifuged and the supernatant was collected. The supernatant was added to Nickel resin
beads (Sigma) and incubated at 4°C for 30 min with rotation. The buffer was removed
and the beads were washed twice with binding buffer. Then the beads were suspended in
elution buffer (6 g/l Tris base pH 7.5, 8.8 g/l NaCl, 1 mM DTT, 34 g/l imidazole, 5%
glycerol), and incubated at 4°C for 30 min. The elution was removed and then run on
SDS-PAGE gels (Sigma) to confirm the presence of the CaDfr1p. SDS-PAGE gels were
run according to the manufacturer's protocol.

Dfr1p enzyme assay
The enzymatic activity of C. albicans Dfr1p was determined using the
dihydrofolate reductase assay (Sigma). The manufacturer protocol was adapted to the
fungal enzyme by scaling down the volume to 100 μl reactions with 88 μl buffer, 6 μl of
a 1mM NADPH stock, 5 μl of a 1 mM DHF stock, and 1 μl of 3 mg/ml purified enzyme.
The loss of NADPH was quantified as the decrease in absorption at OD340nm over a 30minute timeframe. The IC50 was calculated by converting the change in OD340nm per
minute into THF produced per minute and then compared to an untreated control.

Results

DHFR is essential for Candida albicans growth in vitro
To investigate the importance of DHFR in C. albicans, we generated strains with
doxycycline-repressible transcription of DFR1, which encodes DHFR [108]. One allele
of DFR1 was deleted from a strain expressing the tetracycline responsive-transactivator
protein and replaced with the ARG4 selection marker [103]. The promoter of the second
allele was then replaced with one of three tetracycline-repressible promoters - PTETO97,
PTETO98, or PTETO99, which support different basal levels of transcription [102]. DFR1
transcript abundance in strains of each genotype was then compared to a wild-type
control (DFR1/DFR1) by RTqPCR (Figure 2-1). In the absence of doxycycline, the
PTET97-DFR1 strain produces similar levels of DFR1 transcript as the wild-type control,
while PTET98-DFR1 and PTET99-DFR1 strains overproduced DFR1 transcript by ~4 and
~20-fold-respectively. However, in the presence of 5 µg/ml doxycycline, the DFR1
transcript abundance was dramatically reduced in strains of all three genotypes, to below
that of the wild-type control (Figure 2-1). We noted that the PTET97-DFR1 strain grew
slowly compared to the wild-type, even in the absence of doxycycline, suggesting that
Dfr1p production is insufficient, while both PTET98-DFR1 and PTET99-DFR1 grew at a rate
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Figure 2-1. Analysis of DFR1 transcript expression in Candida albicans PTETODFR1 strains.
C. albicans strains of the indicated genotypes were grown to exponential phase in YPD
medium in the presence or absence of 5 μg/ml doxycycline. Total RNA was extracted and
DFR1 transcript abundance determined by RTqPCR. DFR1 transcript abundance was
normalized to that of the ACT1 transcript and then expressed relative to the DFR1
transcript abundance in the wild-type control (SC5314) in the absence of doxycycline.
This data is the average of three biological and technical replicates. * indicates P <
0.0001 compared to the parent strain in the same condition using an unpaired student’s t
test.
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comparable to wild-type (Figure 2-2). We, therefore, selected the PTET98-DFR1 strain for
further study.
Next, we determined if DFR1 expression is required for C. albicans growth in
vitro. When inoculated into rich YPD medium supplemented with 5 µg/ml doxycycline,
the PTET98-DFR1 strain grew to the same cell density as in the absence of doxycycline,
and to the wild-type control (Figure 2-3A). However, when sequentially passaged in the
presence of doxycycline, growth was dramatically reduced by the third passage. This
suggests that DFR1 is essential for C. albicans growth, even in nutritionally rich growth
medium containing high concentrations of folate, as well as metabolites that depend upon
folate for their biosynthesis. The prolonged lag between doxycycline exposure and
growth suppression could indicate that cellular stores of THF permit continued growth in
the absence of Dfr1p until depleted, or that the protein has a long half-life. To distinguish
between these possibilities, we attempted to directly inhibit Dfr1p using methotrexate.
Previous reports have indicated that MTX lacks antifungal activity against C. albicans
[83-85], despite potent inhibition of purified fungal DHFR in biochemical assays [109].
However, we recently reported that MTX has relatively potent and on-target activity
upon whole C. albicans cells in unbuffered YNB medium [104]. We therefore examined
how MTX affected the growth of a wild-type C. albicans strain in YNB medium in doseresponse assays. Significant growth inhibition was observed in this medium, with a
minimum inhibitory concentration (MIC50) of approximately 0.78 µM (data not shown),
without the need for passaging. In addition, passaging of the PTET98-DFR1 strain with
doxycycline in YNB medium resulted in detectable growth inhibition without the need
for passaging (Figure 2-3B). These results suggest that the continued growth of the
PTET98-DFR1 strain upon exposure to doxycycline is likely not due to the utilization of an
intracellular store of THF. Instead, these results are consistent with the Dfr1p enzyme
having a long half-life, resulting in a long-lag before doxycycline-mediated suppression
arrests fungal growth.

Candida albicans has a limited capacity to utilize exogenous sources of folate
Folate biosynthesis deficient mutants of the yeast Saccharomyces cerevisiae are
unable to grow in standard lab medium [110, 111]. However, growth can be restored by
supplementing the medium with extremely high concentrations (≥ 250 µM) of folinic
acid (5-formyltetrahydrofolate) [112]. To determine if exogenous sources of folate are
sufficient to support C. albicans growth in the absence of DHFR activity, we seeded
SC5314 into standard unbuffered YNB medium supplemented with either folic acid,
dihydrofolate (DHF), THF, or 5-methyltetrahydrofolate (5MTHF), and compared growth
in the presence of MTX. Notably, standard YNB medium contains both folic acid (4.5
nM) and PABA, a precursor required for folate biosynthesis. Therefore, MTX sensitivity
was also tested in folate and PABA free YNB medium. The MIC50 of MTX in standard
YNB (0.78 µM) was similar to that in the folate and PABA free medium, indicating that
the folate present in standard YNB medium is not sufficient to affect sensitivity.
Additional supplements of folic acid were completely unable to rescue C. albicans
growth at any soluble concentration (up to 25 µM), and in fact, the MIC50 of MTX
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Figure 2-2. The dfr1Δ/PTETO97-DFR1 strain has a marginal growth defect.
The indicated strains were sub-cultured into YPD broth at approximately 5 X 105 cells/ml
and dispensed into the wells of a 96-well plate. The plate was incubated at 30°C for 48
hours and growth monitored at 30 minute intervals as OD600nm. The values presented here
are the average of twenty-four replicates in a single experiment.

Figure 2-3. Dfr1p is essential for Candida albicans growth in vitro.
A dfr1Δ/PTETO98-DFR1 strain was sequentially passaged in (A) YPD broth, (B) YNB
broth, or (C) fetal bovine serum, each supplemented with 5 µg/ml DOX. Following
inoculation at approximately 5 X 105 cells/ml, each culture was incubated at 30°C for 24
hours and growth was measured after 24 hours as OD600nm. Relative growth was then
expressed as a percentage of the untreated control i.e. minus DOX. The values presented
here are representative of two independent experiments.
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dropped ~10-fold to 0.078 μM (Figure 2-4). Supplementing the medium with either 1
µM DHF, THF, or 5MTHF (Figure 2-5) (well above blood serum concentrations) [113115] had no effect on the MTX mediated growth inhibition of C. albicans. However, the
addition of 250 µM folinic acid to YNB was able to partially restore growth in the
presence of MTX and elevated the MIC50 to ~5 μM (Figure 2-4). Nevertheless, even in
the presence of this excess of folinic acid, MTX inhibited C. albicans growth in a dosedependent manner (Figure 2-6), indicating that the need for Dfr1p activity is not
completely bypassed. Accordingly, we conclude that C. albicans is unable to take up and
utilize sufficient quantities of exogenous folates to sustain growth in standard laboratory
medium.
A combination of dTMP, adenine, histidine, and methionine, each of which
requires folate for their biosynthesis, is sufficient to partially restore S. cerevisiae growth
following treatment with antifolates [110]. However, these supplements were not
sufficient to restore C. albicans growth in the presence of MTX (Figure 2-4). This
suggests that either the provision of exogenous sources of folate-dependent metabolites is
not adequate to bypass the need for de novo folate biosynthesis in C. albicans, or that the
nutritional requirements of this species in the absence of folate are more complex than S.
cerevisiae. Finally, we examined if C. albicans was able to scavenge sufficient folates or
folate-dependent metabolites from blood serum to negate the need for de novo
biosynthesis. The PTET98-DFR1 strain was passaged for three days in 100% Fetal Bovine
Serum (FBS) with or without doxycycline. In the first passage, doxycycline inhibited
growth by ~60%, with increasing growth inhibition seen in subsequent sub-cultures
(Figure 2-3C). Thus, C. albicans is unable to acquire sufficient nutrients from blood
serum to bypass the need for de novo folate biosynthesis.

DFR1 is essential for Candida albicans virulence in a mouse model of disseminated
infection
Next, we determined if DFR1 expression is essential for C. albicans virulence in a
mammalian host using a mouse model of disseminated candidiasis. Female BALB/c mice
were split into two treatment groups: Group 1 was treated with doxycycline in a gel food
formulation from 72 hours before infection, and for the duration of the experiment,
Group 2 was mock treated using unsupplemented gel food. The mice were then infected
with ~5 X 105 yeast cells of PTET98-DFR1 via the lateral tail vein, and their health
monitored for 12 days. Animals exhibiting significant signs of distress were euthanized
and survival compared. All mice in the mock-treated group succumbed to the infection by
day 7 (Figure 2-7), confirming the virulence of the PTET98-DFR1 strain under nonrepressing conditions. In stark contrast, all doxycycline-treated mice survived for the
duration of the experiment. On day 12, surviving animals were euthanized, kidneys
extracted and homogenized, and levels of fungal colonization determined as colonyforming units (CFU). This revealed that 5 of the 8 surviving mice had undetectable levels
of fungal colonization, essentially clearing the infection, with the remaining animals
having extremely low levels of CFU (data not shown). To determine if suppression of
Dfr1p activity is sufficient to resolve an established infection, a second experiment was
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Figure 2-4. Excess folinic acid partially restores the growth Candida albicans in
the presence of methotrexate.
A wild-type C. albicans strain (SC5314) was seeded at 1 X 104 cells/ml into YNB
medium without folate or PABA with the indicated supplements and increasing
concentrations of MTX. After 48 hours of incubation at 30°C, growth was quantified as
OD600nm, and expressed as a percentage of the DMSO treated control. The values
presented here are the average of two replicates and are representative of two
independent experiments

Figure 2-5.

Schematic representation of the folate biosynthetic pathway.
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Figure 2-6. Folinic acid restores growth of Candida albicans in the presence of
methotrexate.
C. albicans strain SC5314 was sub-cultured into (A) YNB medium or (B) YNB medium
supplemented with 500 µM folinic acid at ~ 5 X 105 cells/ml in the presence of increasing
concentrations of MTX. These cultures were established in 96-well plates to facilitate the
monitoring of growth at 30-minute intervals as OD600nm during a 48 hour incubation
period at 30°C. The values presented here are representative of two independent
experiments.
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Figure 2-7. Dfr1p is essential for Candida albicans virulence in a mouse model of
disseminated candidiasis.
Groups of BALB/c mice (N = 6) were inoculated with ~5 x 105 CFU of either the
dfr1Δ/PTET98-DFR1 or the erg11Δ/PTETO-ERG11 via lateral tail vein injections. The
Erg11p strain was included to compare the antifungal efficacy of targeting Dfr1p with a
previously validated target. The mice were monitored three times daily for 12 days, and
those showing signs of distress were humanely euthanized. Mice were treated with 2
mg/g doxycycline or mock treated with vehicle alone provided in a gel food formulation
from 72 hours prior to infection and for the duration of the experiment. The survival of
each group was compared using the log rank test (* is a P < 0.0003).
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performed in which mice were infected with PTET98-DFR1 and doxycycline treatment
initiated 24-hour post-infection. Again, all mice survived the duration of the experiment
(to day 12 post-infection) with initial symptoms resolving within 6 days of doxycycline
treatment. Half of these mice had undetectable levels of fungal colonization in their
kidneys at the end of the experiment (data not shown). These data confirm that Dfr1p is
essential for C. albicans to survive within and cause disseminated disease in a
mammalian host. Furthermore, C. albicans is unable to scavenge sufficient sources of
folate to survive within mammalian tissue, and de novo biosynthesis is required. Indeed
the antifungal efficacy achieved upon repressing Dfr1p expression appears to be similar
to that attained upon suppression of Erg11p expression. Accordingly, DHFR and likely
other FOL pathway enzymes can provide potentially efficacious targets for antifungal
development.

The pH-dependent antifungal activity of methotrexate is likely due to differential
uptake
While MTX has been shown to inhibit fungal DHFR in cell-free biochemical
assays using the purified enzyme, it has also been reported to lack antifungal activity [8385]. Given that these previous studies used RPMI 1640 pH 7 medium, we sought to
account for the antifungal activity we observed in unbuffered YNB medium. We first
confirmed that MTX lacked antifungal activity in RPMI 1640 pH 7 medium (MIC50 >50
μM) (Figure 2-8). Next, to determine if the antifungal activity of MTX is pH-dependent,
dose-response experiments were conducted with SC5314 in YNB medium buffered at pH
5 or pH 7. MTX inhibited C. albicans growth in YNB pH 5 with an MIC50 of ~0.78 μM
(Figure 2-8), but had no effect in YNB pH 7 (MIC50 >50 μM), indicating pH-dependent
antifungal activity. Similar results were obtained in YNB medium lacking folate and
PABA, buffered to either pH 5 or pH 7 (Figure 2-9). In contrast, the PTET98-DFR1 strain
was unable to grow in regular YNB, in folate and PABA free YNB medium at either pH
in the presence of doxycycline (Figure 2-10A), or in YNB supplemented with different
folates (Figure 2-10B) indicating that Dfr1p expression, and by inference de novo folate
biosynthesis is essential at either pH. These data are consistent with the previous findings
of Navarro-Martinez and colleagues that demonstrated MTX does not accumulate within
C. albicans yeast cells at neutral pH [83], and may therefore account for the pHdependent antifungal activity.
Therefore we examined if the antifungal activity of MTX was affected by the
most important drug efflux mechanisms in C. albicans. The susceptibility of a C.
albicans cdr1Δ/Δ mutant, lacking an ATP-dependent ABC family transporter, as well as a
tac1Δ/Δ mutant, lacking a zinc cluster transcription factor that activates the expression of
the Cdr1p and Cdr2p drug efflux pumps [116], is not significantly different from isogenic
or wild-type control strains in YNB at pH 5 (MIC50 0.39 µM) or pH 7 (MIC50 > 6.25 μM)
(Figure 2-11A and B). Similarly, we found that the susceptibility of an mdr1Δ/Δ mutant,
lacking a major facilitator superfamily transporter, which is driven by the proton motive
force at the plasma membrane, and which has been previously implicated in methotrexate
efflux [117, 118], was not significantly different from MDR1+ control strains in
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Figure 2-8. Methotrexate has pH-dependent antifungal activity on Candida
albicans.
Approximately 1 X 104 cells/ml of a wild-type C. albicans strain was seeded into a 96well plate with increasing concentrations of MTX in YNB pH 5, YNB pH 7, and RPMI
pH 7. After 48 hours, the OD600nm was measured and expressed as a percentage of the
DMSO treated control. The results presented here are the averages of two replicates and
are representative of two independent experiments.

Figure 2-9. The presence of exogenous folate does not alter Candida albicans
sensitivity to methotrexate.
C. albicans strain SC5314 was seeded into YNB with or without folate buffered at pH 5
or pH 7 to approximately 1 X 104 cells/ml with increasing concentrations of MTX. After
48 hours at 30°C, growth was quantified as OD600nm and expressed as a percentage of the
untreated control wells. The values presented are the average of two replicates and are
representative of two independent experiments.
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Figure 2-10. Dfr1p is essential for Candida albicans growth in both acidic and
neutral conditions.
The dfr1Δ/PTETO98-DFR1 strain was passaged in (A) YNB pH 5 or 7 as well as the folate
and PABA free YNB at the same pH, (B) YNB pH 5 or 7 supplemented with different
forms of folate with approximately 5 X 105 cells/ml from the previous passage in the
presence of 5 µg/ml doxycycline. The culture was incubated at 30° in a rotating incubator
and after 24 hour the OD600nm was measured. The growth was calculated as a percentage
of the untreated control, i.e. without doxycycline. The values presented here are
representative of two independent experiments.
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Figure 2-11. Efflux pump expression does not substantially alter Candida albicans
susceptibility to methotrexate.
C. albicans cdr1Δ/Δ (A), tac1Δ/Δ (B), or mdr1Δ/Δ (C) strains, or that overexpress CDR1
(A), TAC1 (B),or MDR1 (C) from the PTEF1 promoter, were subcultured to approximately
1x104cells/ml into YNB medium at pH 5 or pH 7 supplemented with a range of
methotrexate concentrations. After 48 hours at 30°C, the growth was quantified by
OD600nm and expressed as a percentage of the value for the untreated wells. The values
presented here are the average of two replicates and are representative of two
independent experiments.
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YNB pH 5 or 7 (Figure 2-11C). The susceptibility of strains engineered to overexpress
either the Cdr1p or Mdr1p efflux pumps [116], was also unaffected. This lends further
support for the hypothesis that the pH-dependent antifungal activity of MTX is a result of
differential cellular uptake or permeability.
To determine if MTX’s pH-dependent activity was specific to C. albicans, we
tested its antifungal activity upon other fungal species in YNB pH 5 and YNB pH 7. Like
C. albicans, MTX showed modest and pH-dependent growth inhibition on C. tropicalis
and C. parapsilosis. In contrast, C. glabrata was insensitive at either pH (Figure 2-12).

Established DHFR inhibitors are unable to inhibit Dfr1p within Candida albicans
cells
Finally, we tested a panel of additional antifolates to examine the relationship
between their antifungal potency and capacity to inhibit C. albicans DHFR. The enzyme
was purified using a 6X-HIS tag [119, 120], and activity detected by measuring the
conversion of NADPH to NADP+ at OD340nm [109]. Dose-response experiments
confirmed MTX to be a potent inhibitor of C. albicans DHFR, while trimethoprim (TMP)
had no activity (Table 2-2), as previously reported [121]. While proguanil (PRO) also
lacked activity (IC50 >10 µM), both pyrimethamine (PYR) and pemetrexed (PTX)
inhibited C. albicans DHFR activity. Consistent with the biochemical data, neither TMP
or PRO were able to inhibit C. albicans growth in YNB medium buffered to either pH 5
or 7 (MIC50 > 25 µM). PYR also failed to inhibit C. albicans growth at either pH (Figure
2-13), suggesting the compound is unable to access DHFR in whole-cells. Similar to
MTX, PTX possessed antifungal activity at pH 5, but not pH 7 in YNB medium,
presumably reflecting pH-dependent cell permeability. It is also possible that the pHdependency of PTX is a result of inhibition of other enzymes, as PTX is known to inhibit
thymidylate synthase and glycinamide ribonucleotide formyltransferase [122].

Discussion
While folate biosynthesis has been successfully targeted to develop antibacterial,
antiprotozoal, and antineoplastic therapies, there have been relatively few efforts to
develop antifungals that target this pathway. Although a combination of trimethoprim and
sulfamethoxazole is used clinically to treat Pneumocystis pneumonia and
Paracoccidiodes infections [82, 123], many of the most important fungal pathogens are
largely insensitive to conventional antifolate drugs [83, 124, 125]. A handful of studies
have attempted to produce derivatives of conventional antifolates with enhanced
antifungal potency, but have failed to yield derivatives with the requisite properties of a
viable antifungal drug. For example, an entire series of sulfone compounds completely
lack antifungal activity against whole C. albicans cells, despite potent inhibition of fungal
DHPS in vitro [124]. Similarly, a large series of diaminopyrimidines, which inhibit
bacterial and human DHFR, have little activity against whole C. albicans cells despite
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Figure 2-12. The pH dependent antifungal activity of methotrexate is species
specific.
Strains of (A) C. albicans, (B) C. glabrata, (C) C. tropicalis, (D) C. parapsilosis were
seeded into YNB medium buffered at pH 5 or pH 7 at approximately 1 X 104 cells/ml in
the presence of a range of MTX concentrations. After 48 hours at 30°C, growth was
quantified as OD600nm and expressed as a percentage of the untreated controls. The values
presented here are the average of two replicates and are represented of two experiments.
The susceptibility to MTX at the highest concentration in each pH was compared to the
other pH using a two-tailed student’s t test (* P < 0.01; ** P < 0.0001).

Table 2-2.
reductase.

Antifolates inhibit the activity of Candida albicans dihydrofolate
Drugs
Methotrexate
Trimethoprim
Pyrimethamine
Pemetrexed
Proguanil
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IC50 (μM)
0.001
> 10
0.1
1.0
> 10

potent inhibition of fungal DHFR in cell-free assays [124]. DHFR inhibitors based on
either quinazoline [126] or pteridine [127] ring scaffolds have potent but pH-dependent
antifungal activity in vitro, which likely explains their lack of efficacy in an animal
model of infection [127]. One factor complicating the interpretation of these findings is
that these studies often used different culture conditions or medium. We, therefore,
considered that the lack of success could be accounted for by infectious species, such as
C. albicans, acquiring exogenous sources of folate from certain growth medium or under
specific conditions in vitro and/or from mammalian tissue in vivo. This would bypass the
need for de novo folate biosynthesis and therefore render antifolate drugs ineffective as
antifungals. However, our results using the doxycycline-repressible DFR1 strain revealed
that DHFR, and by inference de novo production of THF, is essential for C. albicans
growth in a variety of culture conditions including within blood serum as well as the
mammalian host. Aside from extremely high concentrations of folinic acid, medium
supplements of various forms of folate, including the DHFR product THF, were not able
to restore growth upon loss of DHFR expression. Thus, DHFR is a valid and potentially
efficacious target for antifungal development.
These conclusions are further supported by the fact that methotrexate has
relatively potent antifungal activity against C. albicans in the lower pH range. In contrast,
doxycycline-mediated suppression of DHFR activity in the PTET98-DFR1 strain occurred
less rapidly, requiring multiple passages to arrest fungal growth completely. This is likely
a consequence of the indirect mechanism, acting through suppression of DFR1
transcription, rather than direct inhibition of the fungal enzyme’s activity. Nonetheless,
the symptoms observed within mice infected with the PTET98-DFR1 strain resolved fairly
quickly upon doxycycline treatment, indicating that the fungus is highly sensitive to
perturbation of THF production in vivo. We conclude that an antifungal drug acting
through inhibition of DHFR has the potential to provide a highly efficacious antifungal
therapy against C. albicans. However, given that Dfr1p is present in humans and fairly
well conserved between mammals and fungi, selectivity is likely to be an issue.
Interestingly, Anderson and colleagues [95, 128] described trimethoprim derivatives with
an extended central linker with dramatically enhanced potency against C. glabrata
DHFR. However, despite exhibiting selective inhibition of the fungal enzyme over the
human enzyme in cell-free biochemical assays, toxicity to mammalian cells remained an
issue [129]. Accordingly, assuming that inhibition of earlier steps of the folate
biosynthetic pathway (FOL) results in similar antifungal efficacy, it may make more
sense to target those enzymes absent from the mammalian host.
Folate synthesis starts with the conversion of GTP to dihydroneopterin
triphosphate by GTP cyclohydrolase I (Fol2p), which is subsequently condensed with
para-aminobenzoic acid (PABA) to form dihydropteroate by the sequential action of
dihydroneopterin aldolase (DHNA), hydroxymethyldihydropterin pyrophosphokinase
(HPPK), and dihydropteroate synthase (DHPS) [130]. In yeast, the latter three enzyme
activities are provided by a single trifunctional protein, Fol1p, while in filamentous fungi
HPPK and DHPS form a bifunctional enzyme [131]. Dihydrofolate synthase (DHFS;
Fol3p) adds a single L-glutamate residue to produce DHF, which is subsequently reduced
by DHFR (Dfr1p) to produce THF that can accept 1C substituents. Notably, mammals
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completely lack four of the core enzymes required to produce folate, DHNA, PPPK,
DHPS (Fol1p), and DHFS (Fol3p). In the non-infectious yeast Saccharomyces cerevisiae,
the FOL1 and FOL3 genes are both essential for viability under normal culture conditions
[130, 131]. A recent large-scale study using transposon mutagenesis also predicted FOL1
to be essential in C. albicans [133], and an unpublished study has indicated that the
bifunctional FOL1 ortholog is essential in A. fumigatus [134]. Nonetheless, these
enzymes are surprisingly poorly studied in infectious fungi, or indeed S. cerevisiae.
The fact that the doxycycline-repressible DFR1 strain is unable to grow in any
growth medium tested (including those supplemented with THF) under repressing
conditions is consistent with conventional antifolates lacking activity upon the target
enzyme in whole cells, rather than an inherent capacity of C. albicans to bypass the need
for folate biosynthesis. Given that both sulfa-based DHPS inhibitors and various DHFR
inhibitors have demonstrated relatively potent inhibition of the respective fungal enzymes
in cell-free assays [109, 121, 124, 127, 128], the most likely challenge in deriving
antifungals that target folate biosynthesis is achieving sufficient intracellular
accumulation. In the case of mammalian cells, DHFR inhibitors such as MTX, which are
structurally related to folic acid itself, enter primarily through the endogenous folate
transport system [135]. While the lack of a known folate transport system, in theory,
renders fungi vulnerable to antifolates, it simultaneously raises challenges in promoting
the uptake of folate analogs. We consider two possible explanations for the pH-dependent
antifungal activity of MTX. First, fungi could potentially encode a pH-dependent folate
transport system, that enables MTX uptake in more acidic conditions. However, we do
not favor this explanation as such a system would be expected to facilitate the uptake of
folates in the medium themselves simultaneously, and thus bypass the need for de novo
synthesis. Second, and perhaps more likely, MTX uptake in fungi could occur solely
through passive diffusion across the plasma membrane, with the pH dependence simply
reflecting the ionization state of MTX. The pKa of MTX is 4.7 [136]; thus, deprotonation
of the associated carboxylic acid group of MTX at higher pH would confer a negative
charge that may render it membrane impermeable. Either way, we found that the bestcharacterized drug efflux mechanisms in C. albicans, the proton-driven Mdr1p, and ATP
driven Cdr1p and Cdr2p transporters, had little impact on the sensitivity of strain SC5314
to MTX, and therefore do not explain the lack of antifungal activity at neutral pH. Thus,
existing drugs that inhibit DHFR cannot provide antifungals for two main reasons: First,
the fungal enzyme is insensitive to these drugs, presumably due to evolutionary
divergence from the DHFR enzyme in their intended target species. For example, while
trimethoprim apparently possesses some antifungal activity against Pneumocystis
jirovecii given its clinical efficacy, C. albicans DHFR is insensitive [121]. Second, an
inability to access DHFR within the intact fungal cell, issues that are likely determined by
membrane permeability. This likely accounts for the lack of antifungal activity of
pyrimethamine and the pH-dependent activity of MTX and pemetrexed.
C. glabrata was insensitive to MTX at any pH, which indicates that either the
Dfr1p enzyme is structurally distinct or this species has a different acquisition or
permeability of folates. Previous studies have shown that the structure of Dfr1p is
conserved between C. glabrata and C. albicans [137]. However, this same study
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established that while an inhibitor could inhibit both CgDfr1p and CaDfr1p, this enzyme
inhibition did not always correlate with fungal growth inhibition, nor did the inhibition
correlate between species [138]. Therefore, we conclude that the differential in MTX pHdependent activity may be a result of differential uptake of antifolates.
In summary, our results demonstrate that the de novo synthesis of THF is
absolutely required for C. albicans to cause disease within the mammalian host and that
DHFR is a valid and potentially efficacious target for antifungal development. However,
given the structural similarity of fungal and mammalian DHFR and the difficulties in
producing DHFR inhibitors that are active upon whole fungal cells, we propose efforts to
exploit the FOL pathway for antifungal development should focus upon the biosynthetic
enzymes that have not yet been the subject of significant investigation, and which are
completely absent from mammals. In addition, this may enhance the chances of
discovering novel antifolate scaffolds that have activity upon whole fungal cells.
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CHAPTER 3. TARGET ABUNDANCE-BASED FITNESS SCREENING (TAFIS)
FACILITATES RAPID IDENTIFICATION OF TARGET-SPECIFIC AND
PHYSIOLOGICALLY ACTIVE CHEMICAL PROBES2

Introduction
The process of drug discovery, development, and approval often takes more than
a decade, with a recent report estimating the associated costs at over $2.5 billion [62]. As
such, there is an urgent need to increase the efficiency with which new experimental
therapeutics are discovered and developed. This is especially true for antifungal
development, with the newest class of antifungal drugs, the echinocandins, taking 30
years to reach patients [56]. High attrition rates at both the preclinical and clinical stages
prolong this timeline and greatly increase the associated costs. Many failures occur
because hit compounds selected from the initial chemical screening steps lack the
qualities of effective therapies, such as target specificity or membrane permeability. This
is a direct result of the significant limitations of the two conventional drug screening
approaches. Target-based screens require the development of a biochemical assay that is
utilized to identify inhibitors or activators of a purified target protein. While this is often
an effective strategy to identify potent chemical modulators of the target protein, many of
the compounds identified have poor membrane permeability or do not engage the target
protein in its native environment, i.e. whole cells. As such, many hits from target-based
screens lack activity upon whole cells or target specificity and consequently have offtarget effects and/or toxicity. This necessitates costly and often unsuccessful efforts to
improve cell permeability and/or selective target engagement. Thus, hits obtained through
target-based screens have not translated well into clinically useful antimicrobial agents
[64]. Furthermore, many proteins are not amenable to purification or high-throughput
(HTP)-compatible biochemical assays, and thus are not well suited for target-based
chemical screens.
Whole-cell-based screens identify compounds that induce or correct a diseaserelevant phenotype (e.g. inhibition of microbial growth), but the molecular target and
mechanism of action (MOA) of hit compounds are usually unknown. Identification of the
molecular target requires a substantial investment of time and resources, without which
further development and optimization of promising lead compounds toward a viable
therapeutic is severely restricted [65, 66]. Thus, with either strategy, the identification of
pharmacologically-active agents that act via a defined MOA is a multistep process.
Significant increases in the efficiency of drug discovery and development can be
achieved through the rapid identification of physiologically-active hits that act upon a
specific target protein or pathway within living cells. Furthermore, the elimination of
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compounds that lack the requisite target specificity during primary screening would also
yield dramatic cost and time savings.
The purpose of this study was to establish and validate an innovative HTP
screening strategy that can dramatically improve the efficiency with which target-specific
and physiologically-active chemical probes are identified. Our approach is a type of
target-based whole-cell screen (TBWCS), which identifies small molecules that
functionally interact with a selected target protein within intact cells [71]. Like previous
TBWCS, our method, which we have termed target abundance-based fitness screening
(TAFiS), relies on the fundamental principles of chemical genetics- that altering the
abundance of a target protein usually affects a cell’s susceptibility to chemical
modulators of that target [139]. However, TAFiS also integrates the principles of
competitive fitness to enhance the efficiency and sensitivity of the screening assay and
incorporates fluorescent protein (FP) tags to facilitate quantitative measurement of the
chemical-target interaction. To provide proof of principle, we have developed the tools
and methodology necessary to conduct TAFiS in the prevalent human fungal pathogen
Candida albicans. We also validated TAFiS using the previously validated dihydrofolate
reductase (Dfr1p) (Chapter 2). However, the approach we have developed is broadly
applicable and can theoretically be applied to almost any target and in any genetically
tractable microbe.

Materials and Methods

Growth conditions
C. albicans was routinely grown on yeast extract-peptone-dextrose (YPD)
medium agar plates at 30°C, supplemented with 50 μg/mL uridine for ura3Δ/Δ strains.
Selection of C. albicans transformants was carried out on minimal YNB medium (6.75
g/L yeast nitrogen base without amino acids, 2% dextrose, 2% Bacto agar) supplemented
with the appropriate auxotrophic requirements described for S. cerevisiae [98] or with 50
μg/mL uridine.

Plasmid construction
Plasmid pLUX [140] was kindly provided by Dr. William Fonzi (Georgetown
University), pMG2254 [142] and pMG1648 [143] were acquired from the fungal genetics
stock center, pENO1-dTom-NATr [144] was acquired from Addgene, pGateway-TagBFP
[145] was acquired from Evrogen, pFA-GFPγ [146] was kindly provided by Dr. James
Konopka (Stony Brook University), pGEMHIS1, pDDB57 and pRSARG4ΔSpeI [99,
103] were kindly provided by Dr. Aaron Mitchell (Carnegie Mellon University). The C.
albicans expression vectors pKE1 (PACT1) [146] and pKE3 (PENO1) [147] have been
previously described. To construct the expression vector pKE4, 565 bp of the C. albicans
TEF1 promoter (PTEF1) was amplified from strain SC5314 using primers TEF1prF-KpnI
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and TEF1prR-SalI, cut with Kpn I and Sal I, and inserted between the same sites of pKE1
to replace the ACT1 promoter. This formed an expression cassette consisting of PTEF1, a
multiple cloning site (Sal I-Cla I-Eag I-Mlu I-Sph I), followed by 414 bp of the ADH1 3’
UTR sequence. This vector harbors the URA3 selection marker of C. albicans, and can be
targeted for integration at and fully reconstitution the URA3-IRO1 locus of all
CAI4/BWP17 derived lab strains of C. albicans. The pAR8 expression vector was made
by amplifying the PTEF1-MCS-ADH1-3’UTR cassette from pKE4 with primers TEF1prFSpeI and ADH1-3’UTRR-SacI, and cloning the resulting product between the Spe I and
Sac I sites of pRSARG4ΔSpeI. This expression vector can be targeted for integration at
the ARG4 locus of C. albicans.
GFPγ, YFP, mCherry, and dTomato (dTOM) coding sequences were amplified
from pFAGFPγ, pYFPURA3, pMG2254 and pENO1-dTom-NATr plasmids with primers
engineered to incorporate Sal I and Mlu I sites either side of the coding sequence. Each
was subsequently cloned between the Sal I and Mlu I sites of plasmids pKE4 and pAR8.
The coding sequences for tagBFP [8], cerulean (CER) [14], φYFP [15], ZsYellow [16],
and mPlum [17] were codon optimized according to the codon bias of a subset of highly
expressed C. albicans proteins using the OPTIMIZER one codon/one AA program [18].
Synthetic sequences incorporating Sal I and Mlu I sites either side of each optimized
coding sequence were produced by IDTDNA, amplified from the supplied DNA template
using primers AMPF1 and AMPR1, and cloned between the Sal I and Mlu I sites of
pKE4 and pAR8. Plasmids pKE1:DFR1, pKE3:DFR1, and pKE4:DFR1 was made by
amplifying the DFR1 ORF from SC5314 genomic DNA with DFR1ORFF-SalI and
DFR1ORFR-MluI primers, and cloning the resulting product between Sal I and Mlu I
sites of pKE1, pKE3, or pKE4. All plasmid constructs were sequence verified to ensure
the correct cloning of products and absence of unintended mutations.

Candida albicans strain construction
BWP17 [103], and CAI4 [149], were kindly provided by Aaron Mitchell
(Carnegie Mellon University) and William Fonzi (Georgetown University), respectively.
C. albicans was transformed with DNA constructs using the lithium acetate procedure
[100]. Gene deletion strains were constructed using the PCR-based approach described
by Wilson et al. [103]. All pKE3 and pKE4 based vectors (URA3 selection marker),
including pKE1:DFR1, pKE3:DFR1, pKE4: DFR1 and the pKE4 based FP expression
constructs were cut with Nhe I prior to transformation of ura3Δ/Δ recipient C. albicans
strains, to target integration and fully restore the URA3-IRO1 locus. All pAR8 based
vectors (ARG4 selection marker), including the pAR8 based FP expression constructs
were cut with Cla I prior to transformation of arg4Δ/Δ recipient C. albicans strains, to
target integration and restoration of the ARG4 locus.
The DFR1 gene deletion cassette was amplified using primer set DFR1DISF and
DFR1DISR and plasmid pGEMHIS1 (HIS1 selection marker) as template and
transformed into BWP17. Correct integration of the gene deletion cassette to replace one
DFR1 allele was confirmed by diagnostic PCR, using primers HIS1INTR2 and
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DFR1AMPR-SacI as well as HIS1INTF2 and DFR1AMPF-KpnI. To further suppress the
expression of the remaining DFR1 allele, we applied an approach known as Decreased
Abundance by mRNA Perturbation (DAmP) [150] to destabilize the mRNA transcript.
The 3’UTR of the remaining DFR1 allele was targeted for disruption using a deletion
cassette amplified using DFR1DMPF2 and DFR1DMPR2 with pDDB57 as template. The
DFR1/dfr1∆:HIS1 heterozygous strain was transformed with the DAmP cassette,
transformants selected, and the absence of an intact DFR1 3`UTR confirmed by the
absence of a PCR product following amplification with primer pair DFR1DETF and
DFR1AMPR-SacI. Correct insertion of the pDDB57 (URA3) cassette into the 3’ UTR of
DFR1 was also confirmed by the presence of a 968 bp PCR product using primer pair
DFR1DETF and URA3INTR2. Oligonucleotides used in this study are included in
Table 3-1.

Comparison of FP tag brightness
Several C. albicans transformants expressing each FP tag were grown overnight
in YPD medium at 30°C, diluted to approximately 5 X 103 cells/mL in YNB medium and
200 μl of each cell suspension transferred into the wells of a round-bottom 96-well plate.
Following incubation at 30°C for 48 hours, fluorescence intensity at the appropriate
wavelengths and OD600nm were measured using a Cytation 5 plate reader (BioTek
Instruments, Inc.). Excitation and emission wavelengths used for tagBFP, CER, GFPγ,
YFP, φYFP, ZsYellow, dTOM, mCherry, and mPlum were 402/457, 433/475, 488/507,
510/531, 529/550, 533/558, 554/581, 587/612, and 590/649 respectively using a 9 nm
bandwidth for both excitation and emission wavelengths. Fluorescence intensity was then
normalized to growth (OD600nm) and expressed relative to background fluorescence, as
measured in an isogenic, vector alone control strain. For the purpose of pooled
experiments involving both φYFP and dTOM tagged strains, suboptimal wavelengths of
560/590 with 9 nm bandwidth was used for dTOM to minimize spectral overlap.

Antifungal susceptibility testing
Stock solutions of fluconazole, miconazole, voriconazole, terbinafine,
methotrexate, and caspofungin (Sigma-Aldrich) were prepared at 10 mM in DMSO, and
diluted as needed in the same solvent. Each C. albicans strain was grown overnight in
YPD medium at 30°C, diluted to 1 X 104 cells/mL in YNB medium and 100 μl of each
cell suspension transferred to the wells of a round-bottom 96-well plate. An additional
100 μl of YNB medium containing 2X the final desired concentration of each drug was
then added to each well. The final concentration of DMSO was 0.5% for all treatments.
Plates were then incubated at 30°C before growth was quantified after 24 and 48 hours by
measuring OD600nm using a Cytation 5 plate reader (BioTek Instruments, Inc.). The
growth of each strain at each drug concentration was then expressed relative to the minus
drug (DMSO alone) control. The multi-strain competition based experiments were
performed as described above except the individual FP tagged strains were diluted to 1 X
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Table 3-1.

Oligonucleotides used in Chapter 3.

Primer
ACT1prF-BamHI
ACT1prR-EagI
ACT1prSEQF
ADH1-3’UTRR-SacI
AMPF1
AMPF2
AMPR1
AMPR2
ARGINTF2
ARGINTR2
DFR1AMPF-KpnI
DFR1AMPR-SacI
DFR1DETF
DFR1DISF
DFR1DISR
DFR1DMPF2
DFR1DMPR2
DFR1ORFF-SalI
DFR1ORFR-MluI
ENO1prF2-BamHI
ENO1prR-EagI
ENO1prSEQF

Sequence 5’→3’
TCAGGATCCCCAGCCTCGTTTATAATAAACTTAGTC
TCACGGCCGTTTGAATGATTATATTTTTTTAATATTAATATCGAG
CACCAAGATTTATTGCCAACG
TCATCAGAGCTCGAAAACTTGAAACTTGAAAACACC
TGCTGAAGCTTCTTTGAGTGG
TTCAATATTCAATGGATGAGTCCCGGCCGGTCGAC
AGCAAAGAACATGGCAGCACC
CACTCCCATCATGATCATGATTACCGACGCGT
AAGCTAGTGTGGAAAGAAGAG
AATGACTGAATTATGTCGGTC
TCAGGTACCTTGAGTTGTGGACTTAGTGGG
TCAGAGCTCCGACTTTGGAGAGAGAACAGC
GACGTCACCACCAGAACAACG
TTCTTGTTTGATTGAAAAAAAACTTTCACCACTAATCTAGAACTTC
AGGAATAGACAACAGTTTTCCCAGTCACGACGTT
TTATTTTCTTGTCCATAGCGTATAATTATAGGTAAAATCACCTTCCT
TGATATCGTCTTTGTGGAATTGTGAGCGGATA
TATTAGAAGACGATATCAAGGAAGGTGATTTTACCTATAATTATAC
GCTATGGACAAGAAAATAATGTGGAATTGTGAGCGGATA
AACATCRCGAATGAAGGTGTTTGAATAAGTTATTCAATGGCCCTCT
TTTTTTGTTTGTATATTTTGTTTTCCCAGTCACGACGTT
TCAGTCGACAGAACTTCACGAATAGACAAC
TCAACGCGTATAAGTTATTCAATGGCCCTC
TCAGGTACCGTTACAATTGAGATGGAAAGCG
TCAGTCGACTGTTGTAATATTCCTGAATTATC
CTATTTCTTTCCTTTTCTCCC

Engineered restriction enzyme sites are underlined.
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105 cells/mL, mixed 1:1:1 to create the three-membered expression pools, and 1:1:1:1 to
create the four-membered pools, before they were dispensed into the 96-well plates.
Following incubation at 30°C for 48 hrs, OD600nm and fluorescence intensity was
measured as described above. The relative growth of each strain in the presence of drug
was then expressed as a percentage of the growth of the same strain in the minus drug
(DMSO) control co-culture, as measured by fluorescence intensity of the corresponding
FP tag.

Stress phenotypes
Each C. albicans strain was grown overnight in YPD medium at 30°C, the cell
density adjusted to 107 cells/mL in sterile water, and serial 1:10 dilutions performed in a
96-well plate. Cell suspensions were then applied to agar plate surfaces using a sterile
multipronged applicator. Resistance to temperature stress was determined on YPD
medium agar at 37 and 42°C; resistance to osmotic stress was determined on YPD
medium agar supplemented with 1 M sorbitol; and resistance to ionic stress determined
on YPD medium + 1 M NaCl agar. Sensitivity to metal ion stress was also tested on YPD
medium agar supplemented with either 50 μM CuCl2, 50 μM ZnCl2, or 10 mM MnCl2.
Sensitivity to cell wall and membrane stress was compared on YPD medium agar
supplemented with either 5 mM caffeine, 100 μg/ml Congo red or 0.05% SDS. The
ability to utilize non-fermentable carbon sources was also compared on YPG medium
agar (YPD agar with 3% glycerol in place of dextrose).

RNA isolation and RTqPCR
Each C. albicans strain was grown overnight in YPD medium at 30°C then subcultured to an OD600nm of 0.2 and then incubated at 30°C with shaking for 6 hours. Cells
were pelleted by centrifugation before total cellular RNA was extracted using the hot
phenol method [151]. cDNA was synthesized from total RNA using the Verso cDNA
Synthesis Kit (Thermo Scientific) in accordance with the manufacturer's instructions.
Synthesized cDNA was used for the amplification of ACT1 and the gene of interest by
PCR, using SYBR green PCR master mix, according to the manufacturer's instructions.
Gene-specific primers were designed using the PrimerQuest Tool from IDT, synthesized
by Integrated DNA Technologies. The 2−ΔΔCT method was used to calculate changes in
gene expression among the strains [105]. All experiments included both biological and
technical replicates in triplicate.

Chemical libraries
The NIH Clinical Collection (NCC) collection of 719 small molecules was
provided by the NIH Small Molecule Repository. The Prestwick library of 1280 small
molecules was purchased from Prestwick Chemical. The FDA Approved Oncolytic
library (147 compounds) was provided by the NIH Developmental Products Program.
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Finally, the 10,000 compounds from the Myria collection were purchased from SigmaAldrich. All library compounds were supplied at 10 mM in DMSO in 96-well plate
format. These were diluted further in DMSO to final concentration of 1 mM, and 1 μl
volumes dispensed into round-bottomed 96-well plates that were used for the chemical
screens.

Chemical screening
The FP tagged C. albicans strains expressing low, intermediate, and high levels of
target protein were grown overnight in YPD medium at 30°C, diluted to approximately 5
X 103 cells/mL in YNB medium, and mixed 1:1:1 to create the three-membered
expression pools, or 1:1:1:1 for the four-membered pools. 199 μl of the mixed cell
suspension was then added to each well of each library plate, resulting in final compound
concentration of 5 μM. After 24 and 48 hours incubation at 30°C, OD600nm and
fluorescence at the appropriate wavelengths were measured as described above. The
relative fitness differential (Rd) was then calculated for each well as the log10[THi/TLo
fluorescence] and converted to Z-scores using the average and standard deviation of the
Rd score for the whole collection. Hits were called based on a Z-score ≥ (+3) or ≤ (-3) in
two independent replicates. Wells with little detectable C. albicans growth (OD600nm ≤
0.1) were discarded from the analysis.

Results

Design of target abundance-based fitness screening assay
Strains expressing high (THi), low (TLo), or intermediate (TMed) levels of the
desired target protein are constructed, and each is labeled with a spectrally distinct FP
tag. The tagged strains are then mixed together to form an expression pool that is used to
screen and identify compounds that differentially affect the growth of each strain. The
resulting chemically-induced population shift can be detected spectroscopically and
indicates that a compound’s activity depends upon the abundance of the target protein,
therefore establishing a functional interaction between the chemical and target
(Figure 3-1). As such, TAFiS depends upon two key technical challenges: (i) the
capacity to label individual C. albicans strains with sufficiently bright and spectrally
distinct FP tags and (ii) the stratification of target protein expression between THi, TMed,
and TLo strains.

Selection and optimization of fluorescent protein tags
The coding sequences of tagBFP, CER, GFPγ, YFP, φYFP, ZsYellow, dTOM,
mCherry, and mPlum [142, 144-146, 152-155] were cloned into pKE4 which contains the
powerful PTEF1, providing a constant high-level of expression. Each FP expression
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Figure 3-1. Schematic of the Target Abundance-based Fitness Screening (TAFiS)
assay.
A panel of strains expressing high (THi), medium (TMed), or low (TLo) levels of the
selected target are constructed, tagged with spectrally distinct fluorescent proteins (FP),
and pooled. The expression pool is then incubated in the presence of various small
molecules and the relative growth of each strain is quantified by measuring fluorescence.
On-target inhibitors should differentially impact the growth of each strain causing a
chemical-induced population shift that can be detected as a shift in fluorescence, as
compared to the untreated control.
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construct was stably integrated into the genome of wild-type C. albicans strain. Then, 5
transformants of each expression construct were selected and seeded into 96-well plates
in yeast nitrogen base (YNB) medium and then incubated at 30°C for 48 hours.
Fluorescence intensity was measured at the reported excitation and emission maxima of
each FP and compared to a strain transformed with vector alone (untagged). Of those
tested, the three FP tags with the highest signal to background under the assay conditions
were cerulean (CER), green fluorescent protein gamma (GFPγ), and dTomato (dTOM)
(Figure 3-2A). Next, we examined the degree of cross-excitation between these three FP
tags by measuring the fluorescence signal of each tagged strain at each of the other FP
wavelengths. Minimal spectral overlap was detected between CER-, GFPγ-, and dTOMtagged strains (Figure 3-2B), and these three FPs were therefore used in subsequent
work. We next confirmed that the relative abundance of each tagged strain within a
mixed population could be accurately quantified through fluorescence detection. Three
wild-type C. albicans strains tagged with each FP were subcultured together in defined
ratios and incubated in 96-well plates. After 24 and 48 hours, the fluorescence intensity
of each FP tag was measured and plotted against the original inoculum. This produced a
linear correlation with excellent R2 values for each FP tagged strain (Figure 3-2C).
Finally, we examined if high-level expression of CER, GFPγ, or dTOM was detrimental
to C. albicans fitness by comparing the capacity of each tagged strain to endure a variety
of stresses to that of an untagged control strain, including elevated temperature, osmotic
and ionic stresses, as well as the presence of cell wall and membrane-perturbing agents.
While the FP-tagged strains grew marginally slower than the untagged control strain
under standard culture conditions (presumably as a result of the metabolic load of FP
production), the effect was of similar magnitude irrespective of the FP tag expressed. The
FP-tagged strains did not exhibit any additional abnormal phenotypes under any of the
stress conditions tested (Figure 3-3). More recently, we have identified phi yellow
fluorescent protein (φYFP) as an exceptionally bright FP tag with limited overlap with
the other FPs. φYFP also showed the same linear correlation, and phenotypes that the
other FPs had shown.

Altering DFR1 expression dramatically affects Candida albicans methotrexate
susceptibility
Dihydrofolate reductase (Dfr1p) is a historically important drug target for both
antimicrobials and antineoplastic therapies [156-158] but has only recently been validated
as an antifungal target (Chapter 2). Therefore we used Dfr1p to validate the TAFiS assay
and test its reliability to detect on-target inhibitors (Figure 3-4A). We constructed two
DFR1 expression pools, to test the performance of different techniques to alter the target
expression. A DFR1 overexpression strain (DFR1/DFR1/PENO1-DFR1) was produced by
introducing an additional copy of DFR1 into a wild-type (DFR1/DFR1) C. albicans
strain, using an expression vector with the powerful PENO1 transcriptional promoter. To
suppress DFR1 expression, a dfr1Δ/DFR1 heterozygous strain was constructed through
the replacement of one DFR1 allele with the HIS1 selection marker. Since we have
shown that Dfr1p is an essential protein in C. albicans, it is not possible to construct a
dfr1Δ/Δ deletion mutant. Therefore, to further suppress DFR1 expression, a knockdown
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Figure 3-2. The relative percentage of each Candida albicans strain within a
population can be accurately quantified by four spectrally distinct fluorescent
proteins.
Fluorescence was read at the optimal excitation/emission wavelengths reported for five
transformants with each FP. Brightness is expressed as fold-change over an untagged
control strain. (B) The fluorescence of the brightest transformants expressing CER,
GFPγ, φYFP, and dTOM was read at all four FP wavelengths (Ex./Em. 433/475,
488/507, 529/550, 560/590) with a 9 nm bandpass to determine the extent of spectral
overlap. The mean and standard deviations for each are presented. (C) The brightest
strains expressing CER, GFPγ, φYFP, or dTOM were mixed in defined ratios and grown
for 48 hours before fluorescence intensity was measured. Percent fluorescence at each
FP’s wavelength was then plotted against the percent of that tagged strain in the initial
inoculum, resulting in linear correlations with excellent R-squared values for each tag.
Values presented are the mean and standard deviations.
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Figure 3-3. High level expression of the selected fluorescent proteins does not
result in differential susceptibility to a variety of stress.
The brightest transformants expressing CER, GFPγ, φYFP and dTOM were grown
overnight in YPD at 30°C. Cells were washed and resuspended in sterile water at
approximately 1 x 107cells/mL. Ten-fold serial dilutions were pinned on various media
in duplicate and incubated for 48 hours at 30°C, except when indicated otherwise, prior
to imaging. Conditions tested were YPD, YPD at 37°C, YPD at 42°C, YPD + 1 M
sorbitol, YPD + 1 M NaCl, YPD + 50µ M CuCl2, YPD + 50 µM ZnCl2, YPD + 10 mM
MnCl2, YPD + 5 mM caffeine, YPD + 25 µg/mL Congo red, YPD + 0.05% SDS, and
YPG.
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Figure 3-4. Modulating DFR1 expression affects Candida albicans susceptibility to
methotrexate.
Schematic of strain construction of the first expression pool (A) or second expression
pool (D). C. albicans strains were grown in YNB medium at 30°C in the presence of
various concentrations of methotrexate for the first expression pool (B) or the second
expression pool (E). After 48 hours, growth was measured via OD600nm and expressed as
a percentage of that measured in the untreated control. Values presented are the averages
of technical triplicates. (C) C. albicans strains DFR1/DFR1/PENO1-DFR1::CER,
DFR1/DFR1::dTOM, and dfr1Δ/DFR1-DAmP::GFPγ or (D) DFR1/DFR1/PTEF1DFR1::CER, DFR1/DFR1/PACT1-DFR1:: GFPγ, DFR1/DFR1::dTOM, and
dfr1Δ/DFR1::φYFP were combined to create an expression pool. Approximately 1 X 103
cells of the pool were inoculated into the wells of a 96-well plate in the presence of a
range of methotrexate concentrations in YNB. After 48 hours at 30°C, fluorescence was
read at all three FPs’ wavelengths and expressed as a percentage of fluorescence of the
untreated wells. Values presented are the averages and standard deviations of technical
triplicates.
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strain (dfr1Δ/DFR1-DAmP) was produced using a technique known as decreased
abundance by mRNA perturbation (DAmP) [150], to destabilize the mRNA transcript.
RTqPCR confirmed a 30-fold differential in DFR1 mRNA abundance between
DFR1/DFR1/PENO1-DFR1 and dfr1Δ/DFR1-DAmP strains. Next, we confirmed that
changes in DFR1 transcript altered C. albicans susceptibility to the on-target inhibitor
methotrexate. Dose-response experiments confirmed that methotrexate (MTX)
susceptibility differed by ≥ 8-fold between DFR1/DFR1/PENO1-DFR1 and dfr1Δ/DFR1DAmP strains (Figure 3-4B). A second DFR1 expression pool was constructed with an
overexpression strain similar to the first but using the PTEF1 (DFR1/DFR1/PTEF1-DFR1),
which drives higher levels of DFR1 expression than the original PENO1. Then we
constructed a third overexpression strain, with DFR1 driven by the moderate PACT1
(DFR1/DFR1/PACT1-DFR1). RTqPCR confirmed the expression differential to be > 100fold between DFR1/DFR1/PTEF1-DFR1 and dfr1Δ/DFR1. Next, we confirmed that
changes in Dfr1p abundance altered C. albicans susceptibility to the on-target inhibitor
methotrexate. Dose-response experiments confirmed that methotrexate (MTX)
susceptibility differed by ≥ 16-fold between the highest- and lowest- DFR1-expressing
strains (Figure 3-4E).

Chemical-target interactions can be detected as spectroscopic shifts in the FP-tagged
expression pools
Each strain with altered DFR1 expression was each tagged with an FP expression
construct. The DFR1/DFR1/PENO1-DFR1::CER, DFR1/DFR1::dTOM, and dfr1Δ/DFR1DAmP::GFPγ strains were then mixed together to form the first expression pool, and the
DFR1/DFR1/PTEF1-DFR1::CER, DFR1/DFR1/PACT1-DFR1::GFPγ, DFR1/DFR1::dTOM,
and dfr1Δ/DFR1::φYFP were combined to form a second expression pool. Each pool was
examined to determine how an on-target inhibitor affects the composition of the
population. A total of approximately 1 X 103 cells from each DFR1 expression pool,
consisting of the three, or four, strains in equal proportions, were seeded to the wells of
96-well plates in YNB medium and grown for 48 hours in the presence of increasing
concentrations of MTX. Fluorescence intensity was then quantified for each tag and
compared to the minus-drug (dimethyl sulfoxide [DMSO]) control. As expected, a
substantive population shift favoring the highest expression strain was detected in the
expression pool over a ≥ 256-fold and a ≥ 625-fold concentration range of MTX
concentrations compared to DMSO alone for the first and second DFR1 pool respectively
(Figure 3-4C and 3-4F). The same dose-response experiments were performed with a
pool of three wild-type (DFR1/DFR1) strains (i.e., with no DFR1 expression differential),
tagged with CER, GFPγ, or dTOM, no significant spectral shifts were detected (data not
shown). This confirmed that MTX induced a population shift in both DFR1 expression
pools as a result of differential DFR1 expression, rather than interference with FP
intensity. This result demonstrates that chemically-induced population shifts within an
FP-tagged expression pool indicate a highly specific chemical-target interaction. To
further determine the specificity with which TAFiS identifies chemical-probes, the DFR1
strains for the first pool were subcultured together in equal proportions and incubated in
increasing concentrations of known antifungal agents: fluconazole, caspofungin, and
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terbinafine (Figure 3-5). The intensity of each FP was then quantified and compared to
the DMSO control. None of these off-target antifungals induced a population shift in the
first DFR1 pool, supporting that antifungals with MOAs unrelated to folate biosynthesis
do not induce population shifts. Similarly, the Dfr1p strains were subcultured together in
the presence of known antifolates that target another protein in the pathway, specifically
dihydropteroate synthase. Neither sulfamethoxazole nor dapsone induced a population
shift (Figure 3-5), further supporting that populations shifts in this expression pool
indicates a target-specific chemical probe.

TAFiS reliably identifies on-target inhibitors
We next determined if TAFiS can provide the basis of a robust HTP chemical
screening assay. The individual strains for each DFR1 pool were grown to saturation and
then mixed together in YNB medium to a final density of 2 X 105 cells/ml, in equal
proportions to form the 2 separate DFR1 pools. Each pool was then incubated in YNB
medium in 96-well plates with alternating columns of 5 μM MTX, or DMSO. To provide
a single metric of comparative strain growth in each well, a relative fitness differential
(Rd) was calculated as the log10 fluorescence intensity ratio of the highest DFR1
expression strain and lowest DFR1 expression strain in each pool. Z`-factors [159] were
then calculated from the Rd scores of each DFR1 expression pool incubated with or
without MTX. Treatment of the first DFR1 pool with 5 μM MTX yielded a Z` factor of
0.63 ± 0.05 while the second pool yielded a Z` factor of 0.65 ± 0.09, again supporting the
excellent quality of the assay.

TAFiS can provide an effective and efficient high-throughput chemical screen
Finally, we tested the reliability of the TAFiS assay to identify on-target chemical
probes when applied as a HTP-screen. For validation, the two separate DFR1 pools were
used to screen the NIH clinical collection (NCC) of 719 compounds and the Prestwick
library of 1280 compounds at a final concentration of 5 μM, each of which contains
MTX. Wells with a total optical density at 600 nm (OD600nm) of ≤ 0.1 were discarded
from analysis as having populations insufficient to allow reliable detection of population
shifts. Rd scores were calculated for each compound and converted to Z-scores based on
the mean and standard deviation of the DMSO controls. Hits were called based on Zscores of ≥ (+3) or ≤ (-3) in both of two biological replicates. In the 3-membered pool,
only MTX produced a positive Z-score ≥ (+3) (Note that amethopterin, also identified as
a hit, is the same chemical entity). Unexpectedly, 21 compounds induced a statistically
significant inverse population shift (Z-scores of ≤ [-3]), indicating that the highest
expression strain was more sensitive than the lowest expression strain (Table 3-2).
Interestingly, many of the hits that produced negative Z-scores were azole antifungals or
statins. This could be a result of the connection between the ergosterol pathway and the
folate pathway, as the folate pathway supplies the methyl group used in the sterol C24
methyltransferase (Erg6p) [83].
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Figure 3-5. The first DFR1 expression pool only identifies compounds that
specifically interact with the target protein.
C. albicans strains DFR1/DFR1/PENO1-DFR1::CER, DFR1/DFR1::dTOM, and
dfr1Δ/DFR1-DAmP::GFPγ combined in equal proportions to create the first DFR1
expression pool. Approximately 103 cells of the combined pool were inoculated into
YNB medium in the wells of a 96-well plate in the presence of a serial dilution series of
(A) fluconazole, (B) caspofungin, (C) sulfamethoxazole, (D) dapsone, (E) terbinafine.
After 48 hours at 30°C, fluorescence was read at all three FP’s wavelengths, and
expressed as a percentage of fluorescence of the untreated wells. Values presented are the
averages and standard deviations of technical triplicates (N=3) and are representative of
two independent experiments.
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Table 3-2.
Hit list from validation of TAFiS methodology using the first DFR1
expression pool.
Library

NCC

Prestwi
ck

Concentration

5 μM

5 μM

Compound

Mean ZScore

Methotrexate

4.2

Voriconazole

-3.4

Miconazole

-3.6

Triclabendazole

-3.8

Disulfiram

-4.3

Mupirocin

-4.7

Fluconazole

-4.8

Oligomycin A

-6.3

Fluvastatin

-6.6

Cerivastatin

-7.6

Hexachlorophene

-8.0

Amethopterin

6.3
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Structure

Table 3-2.
Library

(Continued).
Concentration

Compound

Mean ZScore

Methotrexate

6.1

Pyrvinium

-4.0

Atorvastatin

-4.1

Pemetrexed

-4.9

Benzethonium

-5.6

Haloprogin

-5.8

Disulfiram

-5.9

Chloroxine

-6.0

Monensin

-7.6

Merbromin

-9.1

Structure

Compounds that were identified when screening the first DFR1 expression pool
consisting of equal proportions of DFR1/DFR1/PENO1‐DFR1::CER, DFR1/DFR1::dTOM,
and dfr1Δ/DFR1‐DAmP::GFPγ cells against the NCC and Prestwick chemical libraries at
5 µM along with their associated Z‐scores for both biologically independent screens.
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The second expression pool identified MTX (and the same chemical matter
amethopterin), raltitrexed, and silodosin as inducing statistically significant population
shifts with positive Z-scores (Table 3-3). Interestingly, the second expression pool did
not identify any statistically significant compounds with negative Z-scores. This reduced
hit rate, especially of compounds causing negative Z-scores, could be a result of the
increased expression differential or the addition of φYFP, both of which could make the
pool more resilient to artifacts of the screen. However, both pools accurately identified
the on-target inhibitor MTX as interacting with Dfr1p, which again supports that both
expression pools reproducibly identify on-target chemical interactions.

TAFiS readily identified novel compounds as potentially interacting with Dfr1p by
screening diverse chemical matter
To further validate our methodology and to identify novel chemical probes for
Dfr1p, we screened a collection of 412 natural products, the FDA Approved Oncology
library (129 compounds), and a selection of 10,000 compounds from the Myria collection
using the second DFR1 pool. These screens were performed as before with each library
compound added to a final concentration of 5 μM. Interestingly, the second DFR1 pool
identified no hits in the natural product library. In the Oncolytic library, MTX was
identified as inducing a positive Z-score, and pemetrexed induced a negative Z-score. Of
the 10,000 compounds from the Myria collection, 3 compounds were identified as
causing statistically significant population shifts, 1 with a positive Z-score, and 2 with a
negative Z-score (Table 3-2). Unfortunately, none of these hits were available for follow
up experiments.
Finally, we repeated the screens with the Prestwick, FDA Approved Oncology,
and Natural Products libraries in YNB without folate or PABA, to determine if the low
concentration of folate in the YNB medium used in the original screens affected assay
interference or hit identification. The second DFR1 expression pool only identified MTX
(and amethopterin) as statistically significant in these libraries under these conditions
(Table 3-4), indicating that the presence of folate and PABA did not interfere with the
identification of chemical-target interactions.
Initial follow up efforts focused on the 3 hit compounds with positive Z scores,
MTX, raltitrexed, and silodosin. As already described, our positive control, MTX,
induces a robust and dose-dependent population shift, however neither raltitrexed nor
silodosin induced population shifts at any concentration tested, suggesting that these do
not interact with Dfr1p (Figure 3-6). The identification of compounds that induced
negative Z-scores was unexpected, as it implies that the low abundance strain has greater
fitness than the high abundance strain. Dose-response experiments were performed with
10 of these compounds in an effort to confirm their activity. An inversely tagged DFR1
pool, where DFR1/DFR1/PTEF1-DFR1 expressed φYFP and dfr1Δ/DFR1 expressed CER,
was utilized to identify compounds that interfered with fluorescent intensity or detection.
Pooled dose-responses showed that merbromin induces dose-dependent fluorescent
interference causing the same fluorescent shifts regardless of which strains expressed
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Table 3-3.
pool.

Hit list from TAFiS validation using the second DFR1 expression

Library

Compound

Z-Score

Prestwick Methotrexate

27.5

Amethopterin

25.2

Raltitrexed

12.5

Silodosin

7.9

Oncolytic Methotrexate

Myria

Structure

11.4

Pemetrexed

-3.4

5-hydroxy-4-(2thienylcarbonyl)(1,2,5oxadiazol-3-yl) 2-thienyl
ketone

3.5

2-(4,5-dibromo-6-hydroxy-3oxoxanthen-9-yl)benzoic acid

-6.6

thio(2,2,4-trimethyl-4phenyl(6-1,2,3,4tetrahydroquinolyl))carbonitrile

-3.9

Compounds that were identified when screening the second DFR1 expression pool
consisting of equal fractions of DFR1/DFR1/PTEF1‐DFR1::CER, DFR1/DFR1/PACT1‐
DFR1::GFPγ, DFR1/DFR1::dTOM, and dfr1Δ/DFR1::φYFP cells against the Prestwick,
Oncolytic, and Myria chemical libraries at 5 µM along with their associated Z‐scores.
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Table 3-4.
Hit list from TAFiS validation using the second DFR1 expression pool
in the absence of folate and PABA.
Library

Compound

Z-Score

Prestwick

Methotrexate

9.4

Amethopterin

9.1

Methotrexate

3.17

Oncolytic

Structure

Compounds that were identified when screening the DFR1 expression pool consisting of
equal fractions of DFR1/DFR1/PTEF1‐DFR1::CER, DFR1/DFR1/PACT1‐DFR1::GFPγ,
DFR1/DFR1::dTOM, and dfr1Δ/DFR1::φYFP cells against the Prestwick, and Oncolytic
chemical libraries at 5 µM in the absence of folate and PABA along with their associated
Z‐scores.
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Figure 3-6. The DFR1 expression pool identified methotrexate as interacting with
Dfr1p.
Approximately 1x103 cells of the second DFR1 expression pool were inoculated into the
wells of a 96-well plate in the presence of a concentration range of (A) methotrexate, (B)
raltitrexed, (C) silodosin in YNB. After 48 hours at 30°C, growth was measured as
OD600nm and is expressed as a percentage of untreated control. Values presented are the
averages of technical duplicates and are representative of two independent experiments.
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which FP tags. In contrast, neither fluconazole, voriconazole, hexachlorophene,
pyrvinium, disulfiram, haloprogin, monesin, fluvastatin, nor mupirocin induced
population shifts in the second DFR1 expression pool (Figure 3-7). The lack of
reproducible population shifts indicates that these compounds do not interact with Dfr1p,
and that the compounds that induced negative Z-scores are false positives.

TAFiS is compatible with 384-well based high throughput screening formats
In order to facilitate increased throughput and efficiency, we examined the
performance of the TAFiS assay in 384-well plates using the second DFR1 expression
pool. Using volumes as low as 20 μl, the C. albicans strains tagged with CER, GFPγ,
dTOM, and φYFP demonstrated excellent signal/background ratios when compared to
the untagged controls (data not shown). Furthermore, the second DFR1 expression pool
yielded Z` factors of 0.71 ± 0.03 when treated with MTX at 5 μM, indicating excellent
performance in the higher density format. Therefore, our approach can reliably identify
target specific chemical probes in a variety of screening formats.

Discussion
The enormous costs and prolonged timelines associated with developing a new
pharmacotherapy underscore the desperate need to increase the efficiency of both
preclinical and clinical phases of drug discovery and development. Herein we describe a
new type of TBWCS that can greatly expedite this process through the selection of
physiologically-active and target-specific hits at the earliest possible stage, the primary
screen. TBWCS have several major advantages over conventional target-based and cellbased screening strategies and, to a large extent, combines the benefits of both into a
single assay. First, chemical probes are selected that functionally interact with a defined
molecular target, providing invaluable insight into each hit’s MOA. Second, the selected
target is presented within its native environment, thus only compounds that can access
and engage the target in its cellular context are recognized. Third, as the measured
outcome is comparative growth of strains expressing different levels of target protein,
TBWCS do not require purification of the target protein itself or a HTP-compatible
biochemical assay of its activity in order to identify relevant chemical-target interactions.
Indeed, this approach can readily be applied to targets that are not amenable to
conventional biochemical assays, such as noncatalytic proteins. Fourth, compounds that
lack specificity (e.g. that engage multiple targets) or which are generally toxic to cells are
unlikely to create the target-dependent fitness differential upon which these approaches
depend, and are thus eliminated at the primary screening stage.
Despite enormous potential advantages, TBWCS are underutilized as a drug
discovery strategy. While several important studies in the pathogenic prokaryotes
Staphylococcus aureus and Mycobacterium tuberculosis have collectively established the
validity of TBWCS to discover on-target chemical probes [71-73], each has been
restricted by several technical issues that have limited efficiency, sensitivity, and/or
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Figure 3-7. Compounds that induced statistically significant negative Z scores do
not induce population shifts.
Approximately 103 cells of the DFR1 expression pool were inoculated into the wells of a
96-well plate in the presence of a concentration range of (A) fluconazole, (B)
hexachlorophene, (C) merbromin, (D) pyrvinium, (E) voriconazole, (F) disulfiram, (G)
haloprogin, (H) monesin, (I) fluvastatin, (J) mupirocin, and (K) pemetrexed in YNB.
After 48 hours at 30°C, growth was measured as OD600nm and is expressed as a
percentage of untreated control. Values presented are the averages of technical duplicates
and are representative of two independent experiments.
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throughput of the screens. Our approach builds upon previous efforts but also
incorporates several technological advances that improve sensitivity and efficiency. First,
previous TBWCS compared only the growth of a knockdown strain, with reduced target
expression, to a reference strain expressing normal levels of the target protein. In our
approach, the effect of test compounds on both knockdown and overexpression strains
can be simultaneously compared to the effect on a reference strain. This improvement
should enhance both the dynamic range and sensitivity of the screening assay to detect
functional chemical-target interactions. Second, previous TBWCS invariably used twoplate assays that compare the growth of the reference and knockdown strains on separate
culture plates. With TAFiS, the overexpression, reference, and knockdown strains are
subcultured together, and thus the relative growth of each strain is compared in a single
well to improve screening efficiency. Third, previous TBWCS were based on
measurements such as colony size or zones of growth inhibition. These outcomes are not
suited for quantitative measurement, automated data collection, or statistical analysis.
Through the incorporation of fluorescent protein tags, TAFiS facilitates straightforward,
quantitative measurements of the relative growth of each strain, providing an outcome
that is readily amenable to statistical analysis. This simplifies the selection, ranking, and
prioritization of hits according to the magnitude of the observed population shift and by
inference the strength of the compound-target interaction.
Finally, in addition to identifying compounds that directly engage the selected
target protein, TBWCS have the potential to identify compounds that indirectly interact
with the selected target protein. For instance, when the abundance of the target protein is
limiting, a compound that interacts with a compensatory/redundant pathway may
preferentially inhibit the knockdown strain’s growth. Compounds with indirect
interactions are potentially important as they may uncover new functional interactions
between distinct cellular pathways or enhance the efficacy of on-target drugs and thus
provide a basis for combination therapy. However, our studies with Dfr1p indicate that
TAFiS is exceptionally reliable at identifying chemical probes that directly interact with
the target. Only 3 hits were identified as causing positive population shifts in the screens
that were not confirmed in follow up assays. Intriguingly, several compounds were
identified that resulted in negative Z scores, indicating that the highest expression strain
is more susceptible to these agents than the lowest expression strain. While the exact
meaning of these interactions is unclear, none of the negative hits that we tested induced
population shifts in follow up assays, indicating that negative Z-scores.
One potential concern with TAFiS is that small molecules may interact with or
selectively quench the fluorescent protein tags, resulting in false positives. However, this
was not a major problem in our assay, which identified very few compounds that
interfered with fluorescent measurement. This is likely because our assay used a selection
of closely related fluorescent proteins, derived from the original GFP (e.g., CER, GFPγ,
and φYFP). This selection should ensure that unique fluorescent protein interactions are a
rare occurrence, as the related FP tags would respond similarly. Nonetheless, such false
positives can be rapidly eliminated using a simple counterscreen to test the effect of each
hit on an inversely FP-tagged pool of strains or a pool of wild-type strains tagged with the
FPs. Chemicals that induce the same spectral shifts in this inverse pool, as in the original

54

pool, interfere with the fluorescent signal or detection and should be eliminated from
further analysis. Finally, the field of fluorescent protein engineering [160, 161], as well as
the instruments used for their detection, is rapidly evolving. We anticipate that as brighter
FPs with more defined spectral profiles become available, there will be the potential to
simultaneously screen multiple expression pools representing multiple target proteins
within a single well. Such multiplexing may facilitate the simultaneous screening against
all components of a pathway and will yield further cost and time savings.
We constructed two different expression pools for DFR1 to investigate the
performance of different techniques. The 4-membered pool had increased expression and
susceptibility differentials compared to the 3-membered pool. Both pools were able to
identify the known on-target inhibitor MTX in chemical screens, but the 3-membered
pool identified no other hits with positive Z-scores, while the 4-membered pool identified
raltitrexed and silodosin, neither of which were confirmed in follow up dose-responses.
Interestingly, the 3-membered pool identified many hits with negative Z-scores in a
single library, while the 4-membered pool only identified 2 across several libraries. The
false positive rate was not consistent between the two pools, which could indicate that
pool specific features, such as the expression differential and the FP tags chosen,
influence the false hit rate. The hits with negative Z-scores could be a result of the FPs
chosen, but most of these hits did not appear to interact with the FP intensity.
Alternatively, the hits could be a result of the differences in strain construction, since the
3-membered pool identified more than the 4-membered pool. However, none of the hits
with negative Z-scores were confirmed in follow up dose responses. Therefore, both
expression pools confirm that TAFiS reliably identifies on-target inhibitors, validating
the approach.
In addition to Dfr1p, we utilized the well-characterized target protein lanosterol
demethylase (Erg11p) to validate this approach. While expression pools for both targets
reliably identified known on-target inhibitors, there were differences between the two
expression pools. First, the Erg11p pool treated with the on-target inhibitor fluconazole
yielded consistently higher Z`-factors than the DFR1 pool treated with MTX; 0.86 ± 0.04
in 96 well plates versus 0.65 ± 0.09, and 0.78 ± 0.03 in 384-well plates compared to 0.71
± 0.03 for the second DFR1 pool. Pools for both targets specifically and reproducibly
identified the expected on-target inhibitors, the Erg11p expression pool identified and
confirmed 2 new compounds that interacted with Erg11p at sub-growth inhibitory
concentrations and were previously unknown to interact with the target. Both
diethylstilbestrol, and hexestrol were identified as causing significant positive Z-scores in
the Prestwick library, and were confirmed in follow up dose-responses. In addition, when
wild-type C. albicans strains were treated with diethylstilbestrol or hexestrol, sterol
profiling was consistent with inhibition of Erg11p. Unfortunately, no such new
interactions were identified using either DFR1 expression pools in the libraries utilized.
Both pools demonstrated the ability to specifically and reliably identify compounds
known to interact with the target of interest.
Moving forward, when applying TAFiS to additional systems, it is crucial to
remember that there are a variety of both target- and compound-specific factors that may
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influence both the magnitude and direction of the observed population shifts. Targetspecific factors may include the magnitude of the target expression differential, the
consequences of hypo- and hyperactivity of the target protein, and the subunit
composition of the target. Maximizing the target protein expression differential between
the strains should increase the range of concentrations over which an on-target probe
differentially impacts the fitness of the strains. For an essential protein, this is limited by
the minimal target protein activity that is sufficient to sustain cell viability. However, for
a nonessential protein, a gene deletion strain can be incorporated into the expression pool.
Accordingly, the population shift induced by a direct chemical-target interaction would
be different, as a target deletion strain should be insensitive to target specific interactions.
Chemical-specific factors that may influence outcomes in the TAFiS assay include the
strength of the chemical-target interaction, the precise mode of action (e.g., inhibition
versus activation, competitive versus non-competitive, active site versus allosteric), and
the specificity of target engagement. Finally, TAFiS is theoretically applicable to any
microbial species that is culturable and genetically tractable, the scope of which was
expanded substantially with the development of CRISPR based systems. We anticipate
the development of closely related methodologies in a variety of other microbes,
including bacterial, protozoan, and fungal pathogens. Due to the ease of recombinant
protein expression in the yeast Saccharomyces cerevisiae, adaptation of TAFiS to this
system could facilitate chemical screens using targets derived from nonculturable
microbes, species not amenable to genetic manipulation, or even disease-relevant human
proteins.
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CHAPTER 4. IDENTIFICATION AND STRUCTURE-ACTIVITY
RELATIONSHIPS OF INHIBITORS OF FUNGAL FATTY ACID
BIOSYNTHESIS

Introduction
Invasive fungal infections (IFIs) are estimated to cause 1.5 million deaths
annually [1]. Candida albicans accounts for 400,000 of these annually, with a mortality
rate of around 40% [1, 7]. Millions more suffer from debilitating mucosal infections or
subcutaneous mycoses [2, 3]. More concerning is that the population of susceptible
individuals continues to rise with the increasing use of broad-spectrum antibiotics,
invasive surgeries, indwelling catheters, and immunosuppressive therapies [12-15]. The
high rates of mortality for patients with IFIs are in part due to the limitations of each class
of systemic antifungal drugs that include patient toxicity, narrow spectrum of activity,
and/or the emergence of fungal resistance [53, 162]. More generally, the clinical efficacy
of currently approved antifungals is also disappointing. Indeed, up to 46% of patients
with disseminated candidiasis will not respond well to fluconazole or other azoles [42,
43, 45-48, 61]. Approximately 28% of patients fail therapy with Amphotericin B [54, 55],
which is the only polyene antifungal approved for systemic use. The most recent
antifungal class, the echinocandins, is only formulated for intravenous administration, has
a narrow-spectrum of activity, and up to 48% of patients fail therapy on caspofungin [44,
48, 54, 55, 60]. As such, there is an urgent need to develop new antifungal drugs with
novel mechanisms of action to overcome the growing problem of antifungal resistance
and improve patient outcomes.
Fatty acids (FA) are a defining constituent of biological membranes and are
therefore essential for life. They also provide important energy stores and posttranslational modifications crucial for attachment and the function of many membranebound proteins [163]. FA synthesis involves repetitive cycles of a seven-step sequence of
reactions that transfer 2 carbon units from malonyl-CoA to extend a hydrocarbon chain
[163, 164]. FA desaturase enzymes subsequently introduce double bonds into the
hydrocarbon chain to yield unsaturated fatty acids (UFAs), which are crucial for
regulating membrane fluidity.
While the FA biosynthetic enzymes of prokaryotes are usually monomeric [165],
they form large multimeric complexes in eukaryotes [166]. These structural differences
have been exploited to derive antibacterial agents, including triclosan and isoniazid that
target the enoyl acyl carrier protein reductase [86, 87]. Recent studies have also revealed
notable differences in the structure of the fungal and mammalian fatty acid synthase
(FAS) complexes [164, 166]. The latter comprises a homodimer of ~540 kDa [167] with
two independent reaction chambers arranged in a flexible X-shaped configuration [164].
In contrast, fungal FAS is a massive 2.6 MDa heterododecameric complex consisting of 6
α (Fas2p) and 6 β (Fas1p) subunits that form a rigid barrel-shaped structure with two
reaction chambers that contain three copies of each domain [164, 166]. The biochemical
mechanism of the fungal FAS starts as an acetyl-CoA is loaded onto the acetyl-
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transferase, located on Fas1p. The acetyl-CoA is shuttled to Fas2p for the 3-ketoacyl
synthase where malonyl-CoA is combined with the acetyl-CoA. The molecule is then
moved to the 3-ketoacyl reductase on Fas2p, where the carbonyl is reduced to an alcohol.
Then the growing carbon chain is moved to the enoyl dehydratase on Fas1p, where the
alcohol group is removed to form a double bond between the 2nd and 3rd carbon from the
acyl carrier protein. This double bond is then reduced by the enoyl reductase on Fas1p, to
form a saturated carbon chain. This sequence is repeated, adding two carbon units until
the chain reaches a 14 or 16 carbon length. This complex is followed by Ole1p, a
stearoyl-CoA Δ9 desaturase which produces monounsaturated fatty acids [168]. Both
FAS and the Ole1p desaturase enzymes are essential for fungal viability [88, 168, 169].
Exogenous supplements of appropriate FAs can partially restore the growth of FAS and
Ole1p deficient mutants in vitro; however, these enzymes are essential for infection
within the mammalian host [88]. C. albicans, Candida parapsilosis, and Cryptococcus
neoformans FAS deficient mutants are all unable to colonize tissue in a mouse model of
disseminated infection, highlighting that FA biosynthesis is essential in vivo [88, 170,
171]. In addition, suppression of FAS or Ole1p expression using a doxycyclinerepressible system was sufficient to clear C. albicans from the tissues of mice with
established disseminated infections [88]. Thus, both FAS and Ole1p can provide
potentially efficacious targets for antifungal intervention. However, attempts to identify
inhibitors of these enzymes are inherently difficult. Ole1p is an integral membrane
protein and the membrane is essential for the integrity and function of the enzyme. The
colossal size and multi-subunit architecture of the FAS complex makes purification of the
functional enzyme impractical [172-175]. As such, it has not been possible to devise
high-throughput compatible biochemical assays that can be used for target-based
chemical screens. However, inhibitors of proteins in the fungal FA pathway have been
reported. Becker and colleagues identified several compounds sharing a 1,2,4triazolidine-3-thione core with antifungal activity against C. albicans and applied a
chemical-genetic approach to infer the target as FA desaturase [88, 176]. This mechanism
of action was further supported by the restoration of fungal growth through the addition
of exogenous UFAs and biochemical data demonstrating these compounds reduced the
UFA content of C. albicans cells. Mor and colleagues identified 2 hydrazide containing
compounds that inhibited sphingolipid biosynthesis in Cryptococcus neoformans but had
poor activity on C. albicans [177].
The purpose of this study is to utilize a whole-cell approach to identify inhibitors
of C. albicans FAS and Ole1p. This was achieved by using the target abundance-based
fitness screening (TAFiS) methodology which we previously validated using DHFR.
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Materials and Methods

Growth conditions
C. albicans was routinely grown on yeast extract-peptone-dextrose (YPD) agar
plates at 30°C, supplemented with 50 μg/ml uridine for ura3Δ/Δ strains. Selection of C.
albicans transformants was carried out on minimal YNB medium (6.75 g/liter yeast
nitrogen base without amino acids, 2% dextrose, 2% Bacto agar) supplemented with the
appropriate auxotrophic requirements described for S. cerevisiae [178] or with 50 μg/ml
uridine.

Plasmid construction
The C. albicans expression vector pKE4 has been previously described [104].
pKE4: FAS1 was generated by PCR amplifying the FAS1 ORF from SC5314 using the
primer pair FAS1ORFF-Sal1 and FAS1ORFR-Mlu1 and cloning the resulting product
between the Sal I and Mlu I sites of pKE4. pKE4: OLE1 was generated by PCR
amplifying the OLE1 ORF from SC5314 using the primer pair OLE1ORFF-Sal1 and
OLE1ORFR-Mlu1 and cloning the resulting product between the Sal I and Mlu I sites of
pKE4. All plasmid constructs were sequence verified to ensure the correct cloning of
products and the absence of unintended mutations.

Candida albicans strain construction
BWP17 [103] was kindly provided by Aaron Mitchell (Carnegie Mellon
University). C. albicans was transformed with DNA constructs using the lithium acetate
procedure [100]. Gene deletion strains were constructed using the PCR-based approach
described by Wilson et al. [103]. All pKE4-based vectors (URA3 selection marker) were
cut with Nhe I prior to the transformation of ura3Δ/Δ recipient C. albicans strains to
target integration at and fully restore the URA3-IRO1 locus. All pGHT-based vectors
(HIS1 selection marker) were cut with Nru I prior to the transformation of his1Δ/Δ
recipient C. albicans strains to target integration at and fully restore the HIS1 locus.
The Ole1p and FAS strains were made using the same methods. The FAS1 gene
deletion cassette was amplified using primer set FAS1DISF and FAS1DISR and plasmid
pRSARG4ΔSpeI (ARG4 selection marker) as a template and transformed into BWP17.
Correct integration of the gene deletion cassette to replace one FAS1 allele was
confirmed by diagnostic PCR, using primers ARG4INTR2 and FAS1AMPR-SacI as well
as ARG4INTF2 and FAS1AMPF-KpnI. The promoter replacement strain was made by
amplifying the promoters of various genes from previously published plasmids [104]
using FAS1PRF and FAS1PRR, and these promoter replacement cassettes were
transformed into the FAS1 heterozygote. Oligonucleotides used in this study are included
in Table 4-1.
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Table 4-1.

Oligonucleotides used in Chapter 4.

Primer

Sequence

FAS1DISF

TGAGGTATAAACTTTCCCCCCTATTTTAGCCTATAATTATTTATATCC
TGTTTCCATATTACACAGTTTTCCCAGTCACGACGTT
FAS1DISR
AGGAATATATTTACCAATCAAATCTTGAGGCTTGACGGACGATTTTG
GAATCTTCTTGCACAAGATGTGGAATTGTGAGCGGATA
FAS1AMPF TGTGTAGATTCAATACAGTCG
FAS1AMPR AGACCCATCGAGCCCAACTGG
ARG4INTR2 AATGACTGAATTATGTCGGTC
ARG4INTF2 AAGCTAGTGTGGAAAGAAGAG
FAS1PRF
CCAACATTTAAAAAACTGTTGGGACTAACCTGCATAGTGAGGGAGG
TCCTGTAGATAAACAACAAAGTTGAACTCCCTTATGGTGC
FAS1PRR
TTTGGTACCAATAAGGTATGTTCAATTGAACCATGAGTTAATTGGAA
AGGTCTATGAGTTGACATACGTCGCATGCTCCCGGCCG
FAS1ORFF- TCAGTCGACATGTCAACTCATAGACCTTTCC
SalI
FAS1ORFR- TCAACGCGTACAGGTCCTTTAAATAGCAAG
MluI
FAS1qF2
CAGGTGGTGTTTCTGGA
FAS1qR2
TACTCATCGTCAATAGGG
OLE1DISF
CAAGTAACACATACTGTTATTACAAGAACTTGAAAGTCAAGACCAA
AACAAATTAGCATTTCACAGTTTTCCCAGTCACGACGTT
OLE1DISR
ATGACAGAAAATGAAAACGAAAAATGAAAGAAAACAAATCAACCC
AGCAATTTTCTATTTGCCTATGTGGAATTGTGAGCGGATA
OLE1AMPF- TCAGAGCTCTCAGCATTAACTTTGGTTGGC
SacI
OLE1AMPR- TCAGAGCTCCTGGACCAGACCACCTTTTGG
SacI
OLE1PRF
AAAGGGGACTAAAATAACAGACATCTACTAGTGAGAATTTCATAAA
TTAAGAAATATTCAAGAGAAGTTGAACTCCCTTATGGTGC
OLE1PRR
GTACCAGCAGCAATGGCATTCAATTTAGTGATATCAACAGTTTCAAG
TTGTTCAACTGTAGTCATACGTCGCATGCTCCCGGCCG
OLE1ORFF- TCAGTCGACATGACTACAGTTGAACAACTTG
SalI
OLE1ORFR- TCAACGCGTACCCAGCAATTTTCTATTTGC
MluI
OLE1qF2
GGTCATTCTCATCGTATTC
OLE1qR2
CTTTGGGTTGGCTTTAG
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Antifungal susceptibility testing
Stock solutions of Cerulenin (Sigma) and ECC190 (UTHSC Medicinal Chemistry
Core) were prepared at 10 mM in DMSO and diluted as needed in the same solvent. Each
C. albicans strain was grown overnight in YPD at 30°C and diluted to 1x104 cells/ml in
YNB medium, and 100 μl of each cell suspension was transferred to the wells of a roundbottom 96-well plate. An additional 100 μl of YNB medium containing 2x the final
desired concentration of each drug was then added to each well. The final concentration
of DMSO was 0.5% for all treatments. Plates were then incubated at 30°C before growth
was quantified after 24 and 48 hours by measuring OD600nm using a Cytation 5 plate
reader (Bio-Tek Instruments, Inc.). The growth of each strain at each drug concentration
was then expressed relative to the DMSO-alone control. The multistrain competitionbased experiments were performed as described above, except the individual FP labeled
strains were diluted to 1x104 cells/ml, mixed 1:1:1:1 to create the four-member
expression pools before they were dispensed into the 96-well, or 384-well, plates.
Following incubation at 30°C for 48 hours, OD600nm and fluorescence intensity at the four
wavelength pairs CER (ex 433/ em 475), GFPγ (ex 488/ em 507), dTOM (ex 560/ em
590), and φYFP (ex 529/ em 550) were measured as described above. The relative
growth of each strain in the presence of drug was then expressed as a percentage of the
same strain's growth in the minus-drug (DMSO-alone) control pool, as measured by the
fluorescence intensity of the corresponding FP label.

RNA isolation and RTqPCR
RNA was isolated using the hot phenol method of RNA isolation described
previously [104]. This RNA pellet was washed with 500 μl of 70% ice-cold ethanol and
collected by centrifugation. The RNA pellet was resuspended in DNase/RNase-free
H2O. cDNA was synthesized from total RNA using the Verso cDNA Synthesis Kit
(Thermo Scientific) in accordance with the manufacturer's instructions. Synthesized
cDNA was used for both the amplification of ACT1 and the gene of interest by PCR,
using SYBR green PCR master mix, according to the manufacturer's instructions. Genespecific primers were designed using the PrimerQuest Tool from Integrated DNA
Technologies (IDT), and synthesized by IDT. The PCR conditions consisted of an initial
denaturation at 95°C for 10 minutes, followed by 40 cycles of denaturation (95°C for 15
seconds), annealing (60°C for 30 seconds), and extension (72°C for 37 seconds).
Software for the 7500 System Sequence Detection Software version 1.2.3 from Applied
Biosystems was used to determine the dissociation curve and threshold cycle (CT). The
2−ΔΔ CT method was used to calculate changes in gene expression among the strains
[105]. All experiments included both biological and technical replicates in triplicate.
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Chemical libraries
The St. Jude Children’s Research Hospital compound collection, of
approximately 800,000 compounds, was passed through a molecular weight filter which
retained molecules weighing 200 to 300 Daltons. This set was further passed through
structural alert filters obtained from the ChEMBL [179] database that removed
compounds containing reactive and interfering substructures (e.g., PAINS compounds).
The resulting set of molecules was clustered using the FCFP_4 fingerprints in Pipeline
Pilot to obtain 10,000 most diverse molecular clusters. The molecules that were the
cluster centers then formed the final "lead-like" set. To cover a different area of the
chemical space than the lead-like set, molecules with molecular weight from 300 to 500
Daltons and aLogP values from 3 to 5 were obtained from the St. Jude collection. This set
of molecules was further filtered to retain molecules having hydrogen bond donor counts
less than or equal to 5, hydrogen bond acceptor counts less than or equal to 10 and sum of
hydrogen bond donor and acceptor counts at least 3. This set was next passed through the
ChEMBL structural alert filters to remove interfering compounds and compounds with
reactive substructures. Finally, the remaining molecules were clustered using the FCFP_4
fingerprints in Pipeline Pilot to obtain ten thousand most diverse compounds that formed
the "drug-like" set.
The Prestwick library of 1280 small molecules was purchased from Prestwick
Chemical. The FDA Approved Oncolytic library (147 compounds), the Natural Products
Set V (419 natural products), and the NCI Diversity Set V (1593 compounds) were
provided by the NIH Developmental Therapeutics Program. Finally, the 10,000
compounds from the Myria collection were purchased from Sigma-Aldrich. All library
compounds were supplied at 10 mM in DMSO in 96-well plate format. These were
diluted further in DMSO to final concentration of 1 mM, and 1 μl volumes dispensed into
round-bottomed 96-well plates, or 0.2 μl volumes were dispensed into 384-well plates,
that were used for the chemical screens.

Chemical screening
The FP-labeled C. albicans strains expressing low, intermediate, reference, and
high levels of the target protein were grown overnight in YPD at 30°C, diluted to
approximately 1 x 104 cells/ml in YNB medium, and mixed 1:1:1:1 to create the fourmember expression pools. Nineteen microliters of the mixed cell suspension (~103 cells)
were then added to each well of the assay plates, resulting in final compound
concentrations of 10 μM. After 24 and 48 hours of incubation at 30°C, OD600nm and
fluorescence intensity at the appropriate wavelengths were measured as described above.
The relative fitness differential (Rd) was then calculated for each well as the log10 THi/TLo
fluorescence and converted to Z scores using the average and standard deviation of the
Rd score of the minus drug controls across the whole collection. Hits were called based
on a Z score of ≥ (+3) and ≤ (-3). Wells with little detectable C. albicans growth
(OD600nm of ≤ 0.1) were discarded from the analysis.
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Restoring growth in the presence of hit compounds by supplementation of fatty
acids
The restoration of growth in the presence of the hit compounds was achieved by
adding 2.5 mM palmitic and oleic acids (16:1 and 18:1) dissolved in tergitol at 100x of
the final concentration to YNB agar, with 1% tergitol as the mock treatment. The
confirmed Ole1p hits were then added to the agar at a final concentration of 25 μM. A
cotton swab was used to streak the untagged Ole1p heterozygote across the plate. The
plates were then incubated at 30°C for 48 hours and photographed at the 24 and 48-hour
timepoint. The restoration of growth was determined visually.

Results

TAFiS provides high-throughput compatible screens to detect FAS and Ole1p
inhibitors
To generate C. albicans strains with differential susceptibility to FA synthesis
inhibitors, we genetically altered the expression of either the FAS1 or OLE1 genes. In
Saccharomyces cerevisiae, FAS1 influences the expression of FAS2 at the mRNA level
through elements located within the FAS2 ORF [180] to keep a consistent stoichiometry
between the subunits. Therefore changes in the mRNA for FAS1 are expected to alter the
abundance of both FAS subunits in C. albicans. A strain that overexpresses the FAS
complex (FASOE) was made by introducing an additional copy of FAS1 under the
powerful and constitutively active TEF1 promoter (PTEF1) into a wild-type C. albicans
strain (FAS1/FAS1 + PTEF1-FAS1) (Figure 4-1A). To lower the expression of the wildtype (FASWT), the first allele of FAS1 was deleted and replaced with the ARG4 selection
marker to generate a FAS1/fas1Δ:ARG4 heterozygote (FASHET). FAS1 is essential in C.
albicans, and thus the second allele cannot be deleted without FA supplementation [88].
Therefore, to reduce transcription further, we attempted to replace the native promoter of
the second FAS1 allele with several promoters, known to support varying levels of
transcription [104]. Only one promoter, PTEF1, which typically drives a high level of
expression under basal conditions, successfully replaced the endogenous promoter to
produce PTEF1-FAS1/fas1Δ: ARG4 (FASPR), possibly indicating that a relatively high
level of FAS1 transcription is necessary to support C. albicans viability. Essentially the
same strategy was used to generate C. albicans strains with altered OLE1 transcription,
including an OLE1/OLE1 + PTEF1-OLE1, an OLE1/ole1Δ:URA3 heterozygous strain, and
a PACT1-OLE1/ole1Δ:URA3 strain, in which transcription of the second allele was
controlled by the moderately strong promoter from the ACT1 gene (Figure 4-1B).
Next, we compared the levels of each transcript in the engineered strains with a
wild-type control strain (FAS1/FAS1 OLE1/OLE1) by RTqPCR. This revealed that when
grown in YPD medium, both the FASOE and FASPR strains expressed approximately 4fold higher levels of the FAS1 transcript than the wild-type control, with the FASHET
strain producing slightly less than the wild-type (Figure 4-2A). Thus, in total, a
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Figure 4-1. Construction of strains with altered FAS1 and OLE1 expression.
Schematic of the construction of strains with altered expression of (A) FAS1 or (B)
OLE1.
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Figure 4-2. Modulating FAS1 and OLE1 expression levels in Candida albicans
affects susceptibility to cerulenin and ECC190 respectively.
(A) C. albicans strains were grown to exponential phase in YPD medium. Total RNA
was extracted and then the (A) FAS1 or (C) OLE1 transcript abundance was determined
by RTqPCR. Target gene transcript abundance was normalized to that of the ACT1
transcript abundance and then expressed relative to the target gene transcript abundance
in the wild-type control (SC5314). These data are the average of three biological and
technical replicates. B) C. albicans strains FAS1/FAS1+PTEF1-FAS1 (FASHI), FAS1/FAS1
(FASWT), fas1Δ/FAS1 (FASMED), and fas1Δ/PTEF1-FAS1 (FASPR) were tagged with CER,
dTOM, GFPγ, and φYFP respectively, and were combined in equal proportions to create
the FAS expression pool. Approximately 1 X 103 cells of the pool was inoculated into
YNB medium in the wells of a 96-well plate in the presence of a serial dilution series of
cerulenin. After 48 hours at 30°C, fluorescence was quantified for all four FPs, and
expressed as a percentage of fluorescence of the untreated wells. Values presented are
the averages and standard deviations of technical triplicates and are representative of two
independent experiments. D) C. albicans strains OLE1/OLE1+PTEF1-OLE1 (OLE1OE),
OLE1/OLE1 (OLE1WT), ole1Δ/OLE1 (OLE1HET), and ole1Δ/PACT1-OLE1 (OLE1LO) were
tagged with CER, dTOM, GFPγ, and φYFP respectively, and were combined in equal
proportions to create the OLE1 expression pool. Approximately 1 X 103 cells of the pool
was inoculated into YNB medium in the wells of a 96-well plate in the presence of a
serial dilution series of ECC190. After 48 hours at 30°C, fluorescence was quantified for
all four FP’s wavelengths, and expressed as a percentage of fluorescence of the untreated
wells. Values presented are the averages and standard deviations of technical triplicates
and are representative of two independent experiments. * indicates P < 0.05 and **
indicates P < 0.001 compared to the parent strain in the same condition using an unpaired
student’s t test.
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differential of just 4-fold was attained in FAS1 transcript abundance between the highest
and lowest expressing strains. The OLE1/OLE1 + PTEF1-OLE1 and PACT1-OLE1/ole1Δ
strains produced approximately 2- and 0.5-fold the amount of OLE1 transcript compared
to the wild-type, respectively (Figure 4-2C). Thus we designated OLE1/OLE1 + PTEF1OLE1 as OLE1HI, OLE1/OLE1 as OLE1WT, OLE1/ole1Δ as OLE1HET, and PACT1OLE1/ole1Δ as OLE1LO. However, the OLE1/ole1Δ strain produced about 5-fold less
OLE1 transcript than the wild-type, creating a total transcript differential of
approximately 10-fold between the OLE1OE and OLE1LO strains. For both genes, strains
of each genotype were tagged through the introduction of an expression vector supporting
the production of high-levels of a spectroscopically-distinct cytoplasmic fluorescent
protein (FP) [104]. Finally, for each gene, we combined the labeled strains into two pools
containing strains with either differential FAS1 or differential OLE1 transcription.
In order to demonstrate that the TAFiS methodology can be applied to identify
inhibitors of FA synthesis, we sought to confirm that on-target inhibitors induced the
expected dose-dependent population shift within the respective FAS1 or OLE1 pools, and
this can be detected spectroscopically. The FAS expression pool was dispensed into 96well plates, at approximately 1 x 104 cells per well, with increasing concentrations of
cerulenin (CRL), a known FAS inhibitor [163], and incubated at 30°C. After 48 hours,
the fluorescent intensity of each tag was quantified to determine the relative abundance of
each strain in the population when compared to the DMSO-alone control. CRL induced a
population shift within the FAS1 pool as expected, but only over a narrow 2-fold range of
concentrations between 3.13 and 6.25 µM (Figure 4-2B). However, a population shift
was observed in the OLE1 pool over ≥ 64-fold range of concentrations of ECC190
(Figure 4-2D), an Ole1p inhibitor [88]. Cerulenin did not induce the population shift that
favored the highest expression strain in the Ole1p pool, nor did ECC190 induce a shift in
the FAS expression pool (Figure 4-3). This confirmed that on-target inhibitors reliably
and specifically induce the anticipated population shifts in the respective FAS and Ole1p
expression pools. Fluorescence-based quantification of the population shifts induced
within the FAS pool by 5 μM cerulenin yielded Z`-factor scores of 0.56 ± 0.06 in the
384-well plate format. Similar experiments with 5 μM ECC190 and the Ole1p expression
pool yielded Z'-factor of 0.70 ± 0.03. This indicates that both the FAS and Ole1p based
TAFiS assays can provide high quality and high-throughput compatible chemical screens
to identify inhibitors of fungal FA biosynthesis.

Identification of potential fatty acid biosynthesis inhibitors
Initially, a total of 27,840 small molecule compounds were selected from the St.
Jude Children's Research Hospital collection, enriched for lead-like and drug-like
molecules. This collection was screened using both the Ole1p or FAS expression pools
separately in unbuffered YNB medium, and compounds causing a statistically significant
population shift versus the DMSO treated controls (as detected spectroscopically by
measuring the FP tags) were identified. Relative fitness differentials (Rd) were calculated
for each well as the log10 ratio of the FP intensity of the high expression strain to the FP
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Figure 4-3. Off-target inhibitors do not cause population shifts that favor the high
expression strain in the expression pools.
(A) C. albicans strains OLE1/OLE1+PTEF1-OLE1 (OLE1OE), OLE1/OLE1 (OLE1WT),
ole1Δ/OLE1 (OLE1HET), and ole1Δ/PACT1-OLE1 (OLE1LO) were tagged with CER,
dTOM, GFPγ, and φYFP respectively, and were combined in equal proportions to create
the OLE1 expression pool. Approximately 1 X 103 cells of the combined pool was
inoculated into YNB medium in the wells of a 96-well plate in the presence of a serial
dilution of cerulenin. After 48 hours at 30°C, fluorescence was quantified for all four
FPs, and expressed as a percentage of fluorescence of the untreated wells. Values
presented are the averages and standard deviations of technical triplicates and are
representative of two independent experiments. (B) C. albicans strains
FAS1/FAS1+PTEF1-FAS1 (FASHI), FAS1/FAS1 (FASWT), fas1Δ/FAS1 (FASMED), and
fas1Δ/PTEF1-FAS1 (FASPR) were tagged with CER, dTOM, GFPγ, and φYFP
respectively, and were combined in equal proportions to create the FAS1 expression pool.
Approximately 1 X 103 cells of the combined pool was inoculated into YNB medium in
the wells of a 96-well plate in the presence of a serial dilution series of cerulenin. After
48 hours at 30°C, fluorescence was quantified for all four FPs, and expressed as a
percentage of fluorescence of the untreated wells. Values presented are the averages and
standard deviations of technical triplicates and are representative of two independent
experiments
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intensity of the low expression strain. The Rd value for each well was then converted to a
Z-score based upon the mean and standard deviation of the DMSO control wells, and
compounds with Z-scores of ≥ (+3) or ≤ (-3) were called as hits. Wells with a total optical
density at 600 nm (OD600nm) of ≤ 0.1 were discarded from analysis as having populations
insufficient to allow reliable detection of population shifts. Using these criteria, 22
compounds were identified as causing a population shift in the FAS pool, and a further
146 in the Ole1p pool. Of these, 59 of the Ole1p primary hits and all 22 FAS hits were
selected for follow up based on the magnitude of the Z-score and availability (Table 4-2).
We screened an additional 13,421 compounds available in the Palmer Lab with
both pools using the Natural Products Set V (419 natural compounds), the FDA
Approved Oncolytic library (129 compounds), the Prestwick library (1280 compounds),
the NCI Diversity Set V (1593 compounds), and a selection of 10,000 compounds from
the Myria collection, a synthetically produced diversity library. Interestingly, neither
expression pool identified any hits in the Oncolytic, Prestwick, or Diversity Set V
libraries. However, the Ole1p pool identified 6 compounds from the Myria collection and
11 natural products as primary hits, while the FAS pool identified 4 compounds from the
Myria collection, and 5 natural products as primary hits. Only one of the compounds
identified by the Ole1p expression pool contained a hydrazide core. Interestingly, 6 hits,
3 each, for Ole1p and FAS had a similar core structure of 1,5-dihydro-2H-dipyridol[1,2a:2’,3”-d]pyrimidine (Table 4-3). Unfortunately, we were unable to acquire any of these
compounds for follow up assays.
Follow up dose-response assays were conducted with each of the 59 Ole1p and 22
FAS selected hit compounds using the respective Ole1p and FAS expression pools, and
the relative fluorescence intensity of each individual strain plotted against concentration.
To eliminate compounds that interfere with the detection of the fluorescent tags, we also
utilized an inversely labeled pool where the FP tags are switched i.e. FASOE tagged with
φYFP and FASPR tagged with CER. None of the 22 hit compounds for the FAS
expression pool caused reproducible population shifts in the follow-up pooled doseresponse, with 3 of the 22 having fluorescent interference. Of the 59 Ole1p hits tested, 33
failed to induce the anticipated dose-dependent population shifts, and an additional 10
interfered with fluorescence detection, and were discarded as false positives. The
remaining 16 caused significant and dose-dependent population shifts in the Ole1p pool
(Figure 4-4). Interestingly, 11 of the 16 confirmed hits had a hydrazide moiety at the
center of the molecule, potentially indicating a novel scaffold for future development.
To determine if these compounds have growth inhibitory activity on wild-type C.
albicans, we determined their relative antifungal potency upon SC5314, a wild-type
clinical isolate [149], using the standard CLSI broth microdilution protocol [181]. Only 2
of the 16 compounds, FAI354 and FAI409, were able to inhibit the growth of SC5314 at
concentrations below 50 μM in RPMI pH 7 medium (MIC50 3.125 and 6.25 μM
respectively). To determine if the Ole1p hits had pH-dependent activity, we tested each
compound's ability to inhibit growth in YNB pH 5, 6, and 7. All 16 Ole1p hits had
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Table 4-2.
Target
Protein
Ole1p

FAS

Description of screening results.

Library
Saint Jude Chemical
Collection
Myria
Prestwick
FDA Oncolytic
NCI Diversity Set V
384 Natural Product
Saint Jude Chemical
Collection
Myria
Prestwick
FDA Oncolytic
NCI Diversity Set V
384 Natural Product

Number of
Compounds
Screened
27840

Primary
Hits
Identified
146

Primary
Hits
Obtained
59

Primary
Hits
Confirmed
16

10000
1280
129
1593
419

6
0
0
0
11

0
0
0
0
0

0
0
0
0
0

27840

22

22

0

10000
1280
129
1593
419

4
0
0
0
5

0
0
0
0
0

0
0
0
0
0
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Table 4-3.
Structures of compounds from the Myria collection identified as
causing statistically significant population shifts in either FAS or Ole1p expression
pools.
Expression
Structure
Pool
Ole1p

Ole1p

Ole1p

Ole1p

Ole1p

Ole1p

FAS

FAS

FAS

FAS
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Figure 4-4. The primary hits from the Ole1p screens induce the expected
population shift in the OLE1 expression pool.
C. albicans strains OLE1/OLE1+PTEF1-OLE1 (OLE1OE), OLE1/OLE1 (OLE1WT),
ole1Δ/OLE1 (OLE1HET), and ole1Δ/PACT1-OLE1 (OLE1LO) were tagged with CER,
dTOM, GFPγ, and φYFP respectively, and were combined in equal proportions to create
the OLE1 expression pool. Approximately 1 X 103 cells of the combined pool was
inoculated into YNB medium in the wells of a 96-well plate in the presence of a serial
dilution of (A) ECC190, (B) FAI354, (C) FAI390, (D) FAI401, (E) FAI409, (F) FAI425,
(G) FAI434, (H) FAI490, (I) FAI496, (J) FAI503, (K) FAI508, (L) FAI573, (M) FAI855,
(N) FAI805, (O) FAI247, (P) FAI804, and (Q) FAI293. After 48 hours at 30°C,
fluorescence was quantified for all four FPs, and expressed as a percentage of
fluorescence of the untreated wells. Values presented are the averages and standard
deviations of technical triplicates and are representative of two independent experiments.
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increased growth inhibition as the pH of the medium increased (Figure 4-5). In addition,
when we tested the confirmed hits in TAFiS dose-response assays with the Ole1p
expression pool, they induced the expected population shift at a lower concentration with
increasing pH. Another observation was that each compound has a lower MIC50 in YNB
medium buffered to pH 7 than in RPMI pH 7 medium. This indicates that not only do
these hits have pH-dependent activity, but also medium-dependent activity.

The supplementation with unsaturated fatty acids restores the growth of Candida
albicans’s growth in the presence of four hydrazide containing screening hits
To further confirm that these compounds affect the production of UFAs, we
determined if supplementation of the medium with palmitic and oleic acids (16:1 and
18:1) was sufficient to restore C. albicans growth in the presence of inhibitory
concentrations of each compound. Unfortunately, 12 of the compounds did not inhibit the
growth of even the OLE1 heterozygote strain under the conditions tested (on YNB
medium agar). However, of the remaining 4 compounds that inhibited C. albicans
growth, the UFA supplements suppressed the growth inhibitory effects of all 4 hit
compounds (FAI354, FAI409, FAI425, FAI496) (Figure 4-6), interestingly all four
contained the hydrazide moiety. This further supports that these compounds inhibit
growth by interfering with the production of UFA.

The Ole1p inhibitors are structurally related and rely on a hydrazide moiety for
activity
In an effort to explore the structure-activity relationship (SAR) of the two
confirmed hits that had antifungal activity against wild-type C. albicans (FAI354 and
FAI409) both of which contained the hydrazide connected to an aromatic ring
(Table 4-4). We kept the thiadiazole and isoxazole rings constant and began modifying
the aromatic ring connected to the hydrazide moiety. Since both leads have fluorine
atoms in the ortho (o) position of the aromatic ring, we looked at para (p) (FAI4427 and
FAI4428) and o, p-difuoro compounds (FAI4439 and FAI4440, Figure 4-7). The
isoxazole-derived compounds did show a slight shift from an MIC50 of 6.25 to 3.125 µM
for the p fluoro compound FAI4427, but the thiadiazole maintained the same potency
regardless of fluorine substitution. Removing all functional groups only resulted in the
MIC50 of the isoxazole derivative increasing to 12.5 µM, while the MIC50 of the
thiadiazole remained unchanged (data not shown). Indeed, when looking at electron
donating groups (methyl and methoxy), the only significant change in MIC50 was
observed with the o methoxy isoxazole FAI4491, whose potency decreased to 50 µM.
Having looked at the 1,2,3-thaidiazole and the 1,2-oxazole moiety of FAI354 and
FAI409, we evaluated the central hydrazide core for its effect on antifungal activity.
Interestingly, when the aryl NH was replaced with a methylene group, both series lost all
potency and nearly all activity (MIC50 >50 µM, FAI4437 and FAI4438, Figure 4-7).
Altering the benzyl amine to a heterocyclic amide did not restore any potency or activity
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Figure 4-5. The presence of unsaturated fatty acids restores the growth of
Candida albicans in the presence of Ole1p inhibitors.
The restoration of growth in the presence of the hit compounds was achieved by adding
palmitic and oleic acids (16:1 and 18:1) dissolved in tergitol at 100x of the final
concentration to YNB medium agar, with 1% tergitol as the mock treatment. The
confirmed Ole1p hits were then added to the cooled molten agar at a final concentration
of 25 μM. A cotton swab was used to streak the untagged OLE1 heterozygote across the
plate and then the plates were incubated at 30°C for 48 hours. The plates were then
photographed at the 24 and 48-hour timepoint. The restoration of growth was determined
visually by the reduction in the growth inhibition.
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Figure 4-6. Ole1p inhibitors have pH-dependent activity on Candida albicans.
C. albicans Ole1p strains OLE1/OLE1+PTEF1-OLE1 (OLE1OE), OLE1/OLE1 (OLE1WT),
ole1Δ/OLE1 (OLE1HET), and ole1Δ/PACT1-OLE1 (OLE1LO) were tagged with CER,
dTOM, GFPγ, and φYFP respectively, and were combined in equal proportions to create
the Ole1p expression pool. Approximately 1 X 103 cells of the combined pool was
inoculated into YNB medium buffered to pH 5 (A, B, and C), 6 (D, E, and F), or 7 (G, H,
and I) in the wells of a 96-well plate in the presence of a serial dilution of ECC190 (A, D,
and G), FAI409 (B, E, and H), and FAI425 (C, F, and I). After 48 hours at 30°C,
fluorescence was quantified for all four FP’s wavelengths, and expressed as a percentage
of fluorescence of the untreated wells. Values presented are the averages and standard
deviations of technical triplicates and are representative of two independent experiments.
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Table 4-4.
Representative compounds from the structure-activity relationship
testing of FAI354 and FAI409.
Fold-Differential of
OLE1OE to OLE1LO

MIC50 (μM)

FAI4424

>256

6.25

FAI4425

>256

3.125

FAI4427

>256

3.125

FAI4428

>256

3.125

FAI4437

>8

>50

FAI4438

0

>50

FAI4439

>256

6.25

FAI4440

>256

3.125

FAI4487

0

>50

FAI4488

0

>50

FAI4489

>2

>50

FAI4490

>4

>50

FAI4491

>32

50

Compound

Structure
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Figure 4-7. Substitutions on the aromatic ring do not alter the on-target activity
of Ole1p hits, but the hydrazine core is essential.
C. albicans strains OLE1/OLE1+PTEF1-OLE1 (OLE1OE), OLE1/OLE1 (OLE1WT),
ole1Δ/OLE1 (OLE1HET), and ole1Δ/PACT1-OLE1 (OLE1LO) were tagged with CER,
dTOM, GFPγ, and φYFP respectively, and were combined in equal proportions to create
the OLE1 expression pool. Approximately 1 X 103 cells of the combined pool was
inoculated into YNB medium in the wells of a 96-well plate in the presence of a serial
dilution of (A) FAI4427, (B) FAI4428, (C) FAI4439, (D) FAI4440, (E) FAI4437, (F)
FAI4438, (G) FAI4487, (H) FAI4488, (I) FAI4489, and (J) FAI4490. After 48 hours at
30°C, fluorescence was quantified for all four FPs, and expressed as a percentage of
fluorescence of the untreated wells. Values presented are the averages and standard
deviations of technical triplicates and are representative of two independent experiments.
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to the level of the original molecule (FAI4487-FAI4490, Figure 4-7). Even modification
of the hydrazide group directly deactivated the compounds (Figure 4-7). Replacing the
aryl N-H with an N-methyl resulted in analogs that failed to induce population shifts in
the OLE1 expression pool. Therefore we conclude that the hydrazide core is essential to
the potency and the chemical-target interaction.

The Ole1p inhibitor ECC190 contains a 1,2,4-triazolidine-3-thione core that
degrades to produce acylhydrazones
As previously stated, Becker and colleagues identified a family of Ole1p
inhibitors that shared a 1,2,4-triazolidine-3-thione core. We hypothesized that the
heterocycle group in the triazolidine compounds, described in the Becker study, might
degrade to a hydrazone (Figure 4-8A) and therefore closely resemble a collection of
potent antifungals (of unknown mechanism) described by Carradori et al. [90], and are
structurally similar to our own hydrazine compounds that interact with the Ole1p
desaturase. We sought to determine the structure-activity relationship of ECC190 and to
confirm that it acts through the same mechanism as the acylhydrazone antifungals
described by Carradori et al.
To determine if the 1,2,4-triazolidine-3-thione antifungals broke down to form
acylhydrazones, we generated an analog of ECC190, FAI000 to facilitate NMR analysis
(Table 4-5). FAI000 was dissolved in DMSO and allowed to degrade over 48 hours at
room temperature. After 16, 24, and 48 hours the NMR spectrum was determined
(Figure 4-8B). The resulting spectrum revealed the breakdown of the 1,2,4 triazolidine
core into a hydrazone, confirming our hypothesis. To provide further evidence that the
hydrazone was the active form of ECC190, we resynthesized the acylhydrazone product,
termed FAI101, and compared its antifungal potency to ECC190 against a wild-type C.
albicans strain. Under the conditions of the CLSI antifungal susceptibility testing, both
FAI101and ECC190 inhibited the growth of a wild-type C. albicans at similar
concentrations (MIC50 3.125 µM) (Figure 4-9). This confirmed that the hydrazone
derivative retained antifungal activity, and suggested that it may be the active form.

The acylhydrazone derivatives of the 1,2,4-triazolidine scaffold act through the same
molecular mechanism
In order to confirm that these compounds that act upon the Ole1p desaturase, we
utilized the Ole1p TAFiS assay similarly to the SAR study with FAI354 and FAI409
(Table 4-4). FAI101 induced the same population shift that was observed with ECC190,
indicating that FAI101’s antifungal activity is dependent upon the expression OLE1,
consistent with the same mechanism of action. To ensure that FAI101 did not interfere
with fluorescent detection, we incubated it with the reciprocally tagged OLE1 expression
pool. FAI101 induced the expected population shift in both the original and reciprocal
pools, i.e. favoring the highest expression strain regardless of the FP, indicating that
FAI101 does not interfere with fluorescent detection. To further confirm that the

77

Figure 4-8. ECC190 degrades into a hydrazone containing compound.
Proposed mechanism for the degradation of ECC190 into the FAI101. (B) NMR
spectrum of the ECC190 analog degrading to the expected hydrazone containing
compound.
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Table 4-5.

Activity and potency of the analogs of ECC190 and FAI101.
Identifier

Structure

Fold-Differential of MIC (μM)
50
OLE1OE to OLE1LO

ECC190

>64

3.125

FAI101

>64

3.125

FAI001

>2

25

FAI002

>32

>50

FAI035

0

>50

FAI036

0

>50

FAI045

0

>50

FAI102

>126

1.56

FAI103

>126

3.125

FAI104

>8

3.125

FAI105

>8

3.125

FAI106

>16

6.25

FAI107

>64

1.56

FAI108

>16

25
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Table 4-5.

(Continued).
Identifier

Structure

Fold-Differential of MIC (μM)
50
OLE1OE to OLE1LO

FAI109

>32

3.125

FAI110

>64

25

FAI111

>16

25

FAI121

>64

3.125

FAI131

>8

50

FAI141

>16

>50

FAI151

>32

>50

FAI156

>16

>50

The fold-differential of OLE1OE to OLELO is a measure of the relative activity of each
compound.
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Figure 4-9. Structure and analysis of ECC190 and FAI101.
Structures of (A) ECC190 and (B) FAI101. C. albicans Ole1p strains
OLE1/OLE1+PTEF1-OLE1 (OLE1OE), OLE1/OLE1 (OLE1WT), ole1Δ/OLE1 (OLE1HET),
and ole1Δ/PACT1-OLE1 (OLE1LO) were tagged with CER, dTOM, GFPγ, and φYFP
respectively, and were combined in equal proportions to create the Ole1p expression
pool. Approximately 1 X 103 cells of the pool was inoculated into YNB medium in the
wells of a 96-well plate in the presence of a serial dilution series of (C) ECC190 or (D)
FAI101. After 48 hours at 30°C, fluorescence was quantified for all four FP’s
wavelengths, and expressed as a percentage of fluorescence of the untreated wells.
Approximately 1 X 103 cells of OLE1WT was inoculated into RPMI 1640 pH 7 and then
seeded into a 96-well plate in the presence of a serial dilution series of (E) ECC190 or (F)
FAI101 and incubated at 35°C. After 48 hours the absorbance at OD600nm was quantified
and expressed as a percentage of the DMSO control. Values presented are the averages
and standard deviations of technical triplicates and are representative of two independent
experiments.
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acylhydrazone derivatives block UFA biosynthesis, we tested if supplementing the
growth medium with 2 mM palmitic and 2 mM of oleic acid was sufficient to restore C.
albicans growth in the presence of growth inhibitory concentrations of FAI101. Indeed,
the UFA supplements rescued fungal growth in the presence of either ECC190 or FAI101
(Figure 4-10), further supporting that FAI101 has the same mechanism of action as
ECC190. Therefore, we explored the SAR of ECC190, and the acylhydrazone, FAI101.

The presence and identity of the thiazole linker is important for potency of the 1,2,4triazolidine scaffold
To determine if the thiazole linker group was essential for inhibition, we
synthesized analogs that removed this linker, joining the 1,2,4 triazolidine and the phenyl
ring directly. Removal of the thiazole group resulted in a molecule, FAI002, that had an
8-fold increase in the MIC50. However, FAI002 retained the ability to induce population
shifts, which indicate that it retained on-target activity. This loss of potency but not
activity indicates that removal of the thiazole linker group does not alter the compound’s
molecular target, but reduces the scaffold’s ability to inhibit fungal growth. Since the
presence of the linker seems important to the potency of the scaffold, we determined if
the identity of the linker affected the activity. We generated an analog, FAI001, which
replaced the linker with a methyl group. Replacement of the thiazole linker resulted in a
greater loss of potency (16-fold increase in the MIC50) than the complete removal, but
this analog retained on-target activity as well. Therefore, it would seem that the presence
and identity of the linker group are crucial to the potency of the molecule but have no
effect on the compound’s ability to engage the molecular target.

The size and aromaticity of the phenyl ring are important for the acylhydrazone to
interact with Ole1p and inhibit the growth of Candida albicans
To determine the effect of hydrophilic groups on the phenyl ring, we synthesized
analogs that placed a nitro group (FAI036) or a carboxyl group (FAI035) at the paraposition of the phenyl ring. Neither of these analogs had detectable growth inhibition at
the concentrations tested (>16-fold increase in the MIC50), and these analogs failed to
induce population shifts in the OLE1 expression pool, indicating that the hydrophilic
additions eliminate the activity of the acylhydrazone.
To determine if the phenyl ring needs to be aromatic, we generated an analog that
replaced the phenyl ring with cyclohexane (FAI045). This compound had an 8-fold
increase in the MIC50 and failed to induce a population shift in the pooled dose responses,
indicating the compound inhibits growth through a different mechanism. This result
demonstrates that the aromatic structure of the phenyl group is necessary for the
compound to function as an Ole1p inhibitor.
To determine if the size of the aromatic structure is important, we produced an
analog that altered the phenyl group to a naphthalene group (FAI111). These analogs
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Figure 4-10. Restoration of growth in the presence of inhibitors with the addition
of unsaturated fatty acids.
The restoration of growth in the presence of the hit compounds was achieved by adding
palmitic and oleic acids (16:1 and 18:1) dissolved in tergitol at 100x of the final
concentration to YNB medium agar, with 1% tergitol as the mock treatment. The
confirmed Ole1p hits were then added to the cooled molten agar at a final concentration
of 25 μM. A cotton swab was used to streak the untagged Ole1p heterozygote across the
plate and then the plates were incubated at 30°C for 48 hours. The plates were then
photographed at the 24 and 48-hour timepoint. The restoration of growth was determined
visually by the reduction in the growth inhibition.
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retained their ability to induce population shifts in the OLE1 expression pool but failed to
inhibit the growth of a wild-type C. albicans strain ( >16-fold increase in MIC50),
indicating that the aromatic structure is necessary, though the size is limited.
To determine the effect of halogen substitutions on the phenyl ring we generated
analogs with meta- (FAI121), para- (FAI131), meta-/para- (FAI141), ortho-/para(FAI151), and ortho-/meta-/para-substitutions (FAI156). The compounds with metasubstitutions retained activity but had an 8-fold increase in the MIC50. The analogs with
para-substitutions retained both potency and activity. In contrast, compounds with meta/para-substitutions retained the activity but had a 16-fold increase in the MIC50 against C.
albicans. Similarly, analogs with either ortho-/para-substitutions, or substitutions at all
three positions, retained their ability to cause population shifts in the OLE1 expression
pool but lost their ability to inhibit the growth of a wild-type C. albicans strain (>16-fold
increase in the MIC50 against C. albicans). Therefore we conclude that none of these
substitutions affected the activity but that only para-substitutions are acceptable to retain
the potency of the scaffold.
The acylhydrazone’s ability to interact with Ole1p and inhibit Candida albicans
growth requires hydrophobic functional groups attached directly to the hydrazone
core
We investigated the two functional groups (R groups) that are directly attached to
the hydrazone core and generated analogs with different lengths of hydrophobic chains as
well as hydrophilic groups. We found that small hydrophobic chains on either or both of
the R groups had no noticeable effect on the activity or potency of the molecule (FAI102,
FAI103, FAI104, FAI105). However, when the R1 and R2 groups form a cyclopentane
(FAI106), there is a 2-fold increase in MIC50, but when R1 and R2 form a cyclohexane
(FAI107), there is a 2-fold decrease in the MIC50. To determine if hydrophilic groups
alter the activity or potency, we generated analogs with short chains that ended in alcohol
groups. Replacing one of the R groups with an alcohol group resulted in a 2-fold increase
in the MIC50 (FAI109, FAI110) while replacing both of the R groups with an alcohol
group resulted in an 8-fold increase in the MIC50 (FAI108). The limited loss of potency
would indicate that the R groups have only a modest effect on the ability to interact with
Ole1p or potency of the molecule, except for hydrophilic groups that reduce the
scaffold’s ability to inhibit fungal growth but do not affect target selectivity.

Discussion
While FA biosynthesis has been successfully targeted to develop antibacterial
agents, there have been few fruitful efforts to develop antifungal compounds for this
pathway. Drugs like triclosan and isoniazid selectively inhibit bacterial growth by
exploiting the fundamental differences between eukaryotic and bacterial FAS, as most
prokaryotes use a type II FAS while eukaryotes typically use a type I FAS [86, 87, 163,
182]. Type II FAS systems use separate peptides for each enzyme, while type I FAS
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combines the enzymatic functions into a single complex formed by two peptides [164,
166].
There have been previous reports in C. albicans, Cryptococcus neoformans, and
Aspergillus fumigatus of inhibitors of the enzymes of the fungal FA pathway, including a
nonselective FAS inhibitor, cerulenin [88, 183]. Cerulenin prevents the synthesis of fatty
acids by binding irreversibly to the 3-ketoacyl synthase and blocking the reaction
between malonyl-CoA and acetyl-CoA. However, cerulenin is also thought to interfere
with sterol synthesis by inhibiting HMG-CoA synthetase [184]. Cerulenin is toxic at 6.7
μM for C. albicans, and C. neoformans, but 0.2 mM for A. fumigatus [185]. A family of
small molecules with a core 1,2,4-thiadiazolidine-3-thione were found to inhibit the
fungal FA desaturase [88]. Their mechanism of action was confirmed by restoring growth
in the presence of the inhibitors by the addition of UFAs, and FA profiling that
demonstrated a substantial loss of UFAs in the membrane after treatment with the
inhibitors. Further, selective inhibitors of fungal sphingolipid biosynthesis in
Cryptococcus neoformans were identified in a large scale chemical screen, but these
compounds had a very narrow spectrum of activity [177]. Unfortunately, none of these
compounds have been developed into clinically-relevant therapies. However, from the
previous efforts, we know that the enzymes are essential and druggable; therefore, the
fungal FA pathway is a prime target for the discovery of novel fungal-specific inhibitors.
We identified very few primary hits for the fungal FAS (31 hits in 41,261
compounds, 0.07% hit rate), and were unable to confirm any of these hits. While this
could simply be a product of the chemical libraries selected, we suspect that this is a
direct result of the limited-expression as determined by RTqPCR and narrow
susceptibility differential to CRL in TAFiS based dose-responses. Unfortunately, the lack
of a validated antibody for the fungal FAS prevented the use of Western blots to compare
the protein levels directly. This narrow window to identify chemical-target interactions
severely limits the pool’s ability to detect on-target inhibitors. The narrow expression
differential is most likely due to the complex regulation of the FAS, as we were unable to
generate FAS strains with low levels of expression, possibly indicating that a high basal
level of FAS expression is required for survival. We attempted to replace the native
promoter with multiple promoters of different strengths, but only the replacement with
one of the highest expression promoters produced viable colonies. In addition, the
overexpression strain with 3 copies of FAS1 had a relatively low basal expression of
FAS1, and the same expression as the promoter replacement strain with a single copy of
FAS1, which supports the notion that the expression of the FAS complex is heavily
regulated at transcription, or in mRNA stability, since the mRNA levels were almost
unchanged. Indeed, there are reports in Saccharomyces cerevisiae that document
regulatory elements within the ORF of FAS2 [180], and cell cycle-dependent regulation
for the entire pathway by an upstream open reading frame that alters translational
efficiency but not the transcription [186]. With this extensive regulation, additional
techniques and strategies will need to be applied to increase the expression differential of
FAS1 if this method is to be applied to identify compounds that interact with this target. It
is also possible that more diverse chemical libraries would have yielded more screening
hits, and therefore better chances to identify novel inhibitors of the FAS complex.
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However we screened 2 distinct libraries that were specifically designed for diversity,
totaling 11,593 compounds with a hit rate of only 0.04%.
We identified 163 primary hits (0.4% hit rate) for the Ole1p and were able to
confirm that 16 of the 59 (27%) tested induced the expected population shift in dose
responses. Interestingly, 11 of the 16 (69%) had a hydrazide core that was not shared
with the previously identified inhibitor ECC190. The hydrazide containing hits are the
most potent compounds of the 16 hits, potentially indicating that the hydrazide core is a
promising candidate for further development. We also found that each of these 11 similar
compounds, and ECC190, has pH and medium-dependent inhibition of fungal growth,
which will need to be considered in future development. Furthermore, while most of the
16 compounds that induced population shifts were not potent enough to inhibit growth,
the addition of UFA was able to restore fungal growth in the presence of the most potent
of the primary hits, indicating that the compounds exert growth inhibition through
interactions with the desaturase. We attempted to biochemically confirm the Ole1p hits
using fatty acid profiling as Xu and colleagues did when they identified ECC190 [88].
However, the technique provided inconsistent results, for us, even on untreated samples
from the same culture.
We identified a series of hydrazide-containing compounds that interact with the
fungal FA desaturase. However, only a few of these compounds were potent enough to
inhibit the growth of the wild-type strain at the concentrations tested. Therefore we
explored the structure-activity relationship of the two most potent hydrazide compounds.
The addition or removal of the functional groups on the aromatic ring appears to
contribute very little to the potency or the on-target activity of the two compounds.
However, any alteration to the central hydrazide core completely eliminated the
compound’s ability to induce a population shift in the expression pool, indicating that the
central hydrazide is essential for these compounds to function as fungal FA desaturase
inhibitors. Hydrazide containing compounds have been reported to have high reactivity
and toxicity [187, 188] and this limitation will have to be addressed in the future
development of these compounds. Furthermore, we were unable to increase the potency
of the scaffold, which will need to be considered for future development. Similarly, the
toxicity to mammalian cells for these compounds is unknown and will need to be
determined before future development.
In addition, we developed analogs to a previously identified Ole1p inhibitor,
ECC190, and the degradation product, FAI101. We confirmed that the 1,2,4 triazolidine3-thione broke down into the acylhydrazone, which is similar to a compound previously
reported on by Mor and colleagues [170] and Carradori and colleagues [90]. Mor and
colleagues identified 2 compounds that are hydrazone/hydrazide combinations with
aromatic rings on both sides, termed “hydrazycins,” which they postulated that these
compounds inhibit fungal sphingolipid synthesis in C. neoformans [170], however, these
compounds had poor activity against C. albicans. Carradori et al. synthesized (thiazole-2yl)hydrazine derivatives, very similar to FAI101, in order to improve their antifungal
spectrum and drug-like properties of a previously identified scaffold [189]. They reported
that these had anti-Candida activity similar or better than the antifungal clotrimazole, and
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had limited cytotoxicity on Hep2 cells, a human laryngeal epidermoid carcinoma of the
larynx. However, the molecular target or mechanism of these anti-candida agents was
never investigated, which we suggest to be the fungal FA desaturase.
Our own SAR efforts discovered that most alterations we made did not alter the
molecular target of either ECC190 or FAI101. The exceptions to this observation were
the nitro/carboxyl group on the phenyl ring, and the loss of the aromatic nature of the
ring. In contrast, the potency of the molecule was more responsive to alterations with the
hydrophobic R groups of the molecule contributing very little to the overall potency of
the molecule, but hydrophilic additions eliminated potency without altering target
engagement. The presence and identity of the thiazole linker was found to be important
for the potency. Similarly, substitutions on the phenyl ring decreased the compound’s
potency, except for the para-substituted halogens. To conclude, the R groups of the
compound are flexible for both the activity and the potency, while the phenyl ring has a
larger impact on the potency. Collectively, these 2 SAR studies suggest that the TAFiS
methodology could prove useful to ensure that analogs developed in SAR retain the
original molecular target within whole-cells.
Both FAS and Ole1p had been previously validated as antifungal drug targets and
both have established chemical probes, suggesting that they are druggable targets [88,
185]. We identified a novel scaffold that inhibits the growth of C. albcians by interacting
with Ole1p that is structurally distinct from the previously identified ECC190. The novel
scaffold supports the conclusion that Ole1p is a valid and druggable antifungal target. In
addition, the identification of the novel scaffold demonstrates that TAFiS can provide an
efficient methodology to perform chemical screens that identify inhibitors of traditionally
challenging drug targets. In the application to other targets, several target-specific factors
will need to be considered. Maximizing the target expression between the strains of the
expression pool should increase the range over which on-target inhibitors can be
detected. The maximization of expression differential can be challenging with targets like
FAS, as multiple forms of regulation directly oppose the stratification of expression.
Heavily regulated targets will require additional methods of target stratification, such as
silencing mRNA, destabilization of the mRNA (DAmP), activation/deactivation
mutations in the target enzyme, and other techniques to alter the sensitivity to on-target
inhibitors. Another factor is the secondary effects of altering the target expression, such
as membrane permeability or sensitivity to other stresses. Logically, alterations in the
structure of the plasma membrane through alterations in the sterol biosynthesis or fatty
acid biosynthesis pathways could alter membrane permeability. This concern did not
appear to influence our results with FAS, Ole1p, or Erg11p but should still be considered.
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CHAPTER 5.

CONCLUSION

Introduction
IFIs are estimated to kill over a million people worldwide each year [1] even with
our current antifungal treatments. In addition, resistance to existing antifungal therapies is
increasing [42], and all classes have high rates of clinical treatment failures [44-48, 54,
55, 60, 61]. Therefore, new antifungal therapies are urgently required with improved
clinical efficacy. One of the major challenges to discovering novel antifungals is the
inefficiency of traditional chemical screening methods [63]. Traditional approaches to
drug discovery often yield compounds that lack the characteristics of effective therapies,
such as membrane permeability or the ability to engage the molecular target in its native
context, i.e. within whole-cells [64], and substantial efforts are required to improve these
compounds, extending the timeline and cost of drug discovery. Therefore, the objective
of this work was to improve the efficiency of the early stages of drug discovery by
establishing and validating the TAFiS methodology, a second-generation target-based
whole-cell screening strategy based on the principles of chemical genetics and
competitive fitness. TAFiS was specifically designed to increase the efficiency and
sensitivity of chemical screening and lead compound selection. By utilizing Dfr1p, which
we validated as a promising antifungal target in this work, we demonstrate that our
approach reliably and efficiently detects compounds that functionally interact with a
defined molecular target in whole cells. We were also able to show that our approach, in
applying the method to fungal fatty acid desaturase, can identify novel and
physiologically-active inhibitors of proteins that are incompatible with traditional high
throughput chemical screening approaches.

Chapter 2: Dihydrofolate Reductase Is a Valid Target for Antifungal Development
in the Human Pathogen Candida albicans
The folate pathway has been exploited to develop both antibacterial and
antineoplastic agents, but has received very little attention for antifungal development.
While there have been a few attempts to make antifolates with antifungal activity [129,
156], none of these efforts have yielded a viable therapeutic. Indeed, no previous effort
had unequivocally demonstrated that DHFR is essential for fungal survival in vitro or in
vivo. To test this, we generated a strain of C. albicans in which the transcription of DFR1
was doxycycline repressible (PTETO-DFR1) and determined if it was required for growth
in vitro and pathogenicity in the mouse model of disseminated candidiasis. Our results
confirmed that DHFR is indeed required for C. albicans growth in vitro. More
importantly, the suppression of DFR1 expression in vivo was sufficient to prevent
mortality in mice infected with PTETO-DFR1. To our knowledge, this is the first report
that Dfr1p is essential for pathogenicity in vivo, demonstrating that it is a potentially
efficacious target for antifungal development.
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In addition, we observed that C. albicans has a limited ability to take up or utilize
exogenous folates. Only folinic acid was able to partially rescue growth inhibition caused
by MTX, and other forms of folate failed to restore growth of the PTETO-DFR1 strain in
the presence of DOX, indicating that C. albicans cannot acquire or utilize sufficient
quantities of folate to support growth in the absence of Dfr1p activity. Collectively, our
results suggest that C. albicans can not acquire sufficient folate derivatives from the
mammalian host to survive in the absence of Dfr1p activity. Mammalian cells have a
specialized folate transport system that takes up DHF, which is then converted to the
active THF by DHFR [136]; in contrast, the majority of prokaryotes and microbial
eukaryotes lack folate transporters and must synthesize folic acid de novo. Therefore, it is
unlikely that such a transport system exists in C. albicans as the uptake of folates would
be expected to restore growth in the presence of antifolates and repression of DFR1
expression.
While DHFR has been successfully exploited for many years in antibacterial and
antineoplastic treatments, we have established it as a valid target for antifungal drug
development. The validation of DHFR as a target for antifungal development allows the
leveraging of previous efforts that extensively characterized both DHFR and antifolate
compounds to devise fungal-selective inhibitors of the folate biosynthetic pathway. Since
humans acquire folate from their diet, and microbes synthesize it de novo, several
enzymes of the folate biosynthetic pathway are absent in mammals, and may provide an
opportunity to develop fungal selective inhibitors of the pathway. DHFR is one of the
few proteins in the pathway that is present in humans, however, the relatively wellconserved structure of the fungal and human enzymes likely to pose a significant
challenge in developing fungal selective inhibitors and viable therapeutics. While overall
human and fungal DHFR is well conserved, there is a basis for selective inhibition as
multiple active site residues are not conserved, and the active site is 1.4 Å larger in the
fungal DHFR than the human [121]. Indeed, previous reports have shown that
trimethoprim analogs, specifically extended to enhance the interactions with the fungal
active site, inhibited purified fungal DHFR in the nanomolar range but purified human
DHFR in the micromolar range, however toxicity to mammalian cells remained a concern
[129]. Therefore, it is probable that the folate pathway proteins without mammalian
orthologs are more promising targets with respect to selectivity as small molecules that
inhibit these enzymes are less likely to interfere with mammalian folate metabolism and
therefore cause less toxicity in humans. Of note, Fol1p and Fol3p are completely absent
in humans and poorly characterized in pathogenic fungi, but assuming they are also
required for fungal pathogenicity in vivo would make ideal antifungal targets. Neither of
these proteins has yet been unequivocally demonstrated to be essential for pathogenic
fungi growth or pathogenicity in any model, but Fol1p, a trifunctional enzyme that makes
up the majority of the pathway, contains the active site dihydropteroate synthase, a
protein already targeted by sulfa antibiotics.
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Chapter 3: Target Abundance-Based Fitness Screening (TAFiS) Facilitates Rapid
Identification of Target-Specific and Physiologically Active Chemical Probes
The TAFiS methodology was designed to address the major failures of traditional
chemical screening used at the early stages of drug discovery. Conventional approached
yield many hits lacking target-specificity and/or membrane permeability and should
increase the efficiency with which promising lead compounds with potential for
development into viable therapeutics are identified. In our method, strains with altered
expression of the target protein are constructed and labeled with a spectrally distinct FP,
and then mixed together to form the expression pool that is used to identify compounds
that differentially affect the growth of the strains. The resulting population shifts,
detected spectroscopically, indicate that the compound’s activity is dependent upon the
expression of the target.We developed spectroscopically distinct fluorescent protein
constructs that had sufficient signal intensity to allow the quantification of an individual
strain’s growth within a mixed population. As expected, stratification of the expression of
DFR1 produces strains with altered susceptibility to the on-target inhibitor, MTX. These
strains were mixed together into two separate expression pools and incubated in the
presence of MTX, which induced a population shift in both expression pools, indicating
that they accurately identify on-target inhibitors. Additionally, incubating the DFR1
expression pools with off-target antifungals did not induce population shifts, further
confirming the specificity of the assay. By combining the strains with altered target
expression together, we achieved higher sensitivity and throughput over screening
separate single strains against chemical libraries to identify chemical-target interactions
as a result of competitive fitness accentuating chemically-induced fitness defects in the
low expression strains.
TAFiS relies on the ability to construct strains with altered susceptibility to
compounds that interact with the selected protein and to detect population shifts in mixed
cultures using fluorescent protein tags. Heavily regulated targets, especially those that
have significant post-transcriptional or post-translational regulation, may have
confounding mechanisms that oppose efforts to stratify target expression into the high,
medium, and low strains. To use TAFiS against these targets, techniques that altered the
stability of the mRNA[150] or abundance of the protein [190, 191] would be more useful
than the transcriptional stratification we utilized. This is probably why the FAS
expression pool had such a limited expression differential, as both subunits are known to
under many forms of regulation at both transcriptional and translational levels [186].
Similarly, target proteins that do not have established chemical probes hinder the
validation of the TAFiS assay for that target. Without a known interactor, the native
susceptibility of the constructed strains remains unknown, and thus a pool of strains with
altered susceptibility is challenging as there is no confirmation that target interaction
causes the expected population shift. Likewise, compounds or phenotypes that interfere
with the detection of the fluorescent signal will also hinder the assay’s ability to detect
chemical-target interactions. Compounds that fluoresce in the wavelengths used for the
FPs or quench the fluorescence of the FPs may yield false positives or negatives. We do
not expect this to be a major problem as we identified very few compounds in our
screening that were confirmed to interfere with fluorescence detection, however it is
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possible that the reliance on the dTOM FP in the first DFR1 pool was partially
responsible for the large number of hit compounds that induced negative Z-scores, which
were discarded as false positives when they failed to induce the population shift in doseresponse TAFiS assays. We expect many of the fluorescent challenges of TAFiS to be
met with advances in the fluorescent protein engineering field, with the production of
brighter and more spectrally distinct proteins that are less likely to have compound
fluorescent interference.
The TAFiS assay reliably identified inhibitors in both 96- and 384-well plate
format. In theory, TAFiS could also be applied in higher throughput screening formats to
increase throughput, efficiency, and reduce cost further. However, in the transition from
96-well plates to 384-well plates, the fluorescent signal was reduced by 60% on average.
Therefore the transition to 1536-well plates will have to address the reduction in
fluorescent signal, either through more sensitive detection methods or brighter
fluorescent proteins. Similarly, the plate reader takes approximately 17 minutes to
quantify all four fluorescent wavelengths and the optical density of a single 384-well
plate. Therefore, our largest library of 10,000 compounds with 32 screening plates takes
over 9 hours to process the entire library. The use of non-commercial automation has
reduced the personnel hours required, but increased the amount of time each plate is
incubated at room temperature before each signal is quantified, which is suboptimal for
the consistency of the assay. Therefore, to increase the throughput of the TAFiS assay, a
faster method to quantify each signal in each well would have to be addressed.
Further, we demonstrated that when applied as a primary chemical screen, TAFiS
rapidly and specifically identifies compounds known to interact with the selected
molecular target in whole cells. This methodology can potentially be applied to nearly
any protein in any genetically tractable microbe. TAFiS’s ability to rapidly identify
compounds that functionally interact with the molecular target, and the elimination of
compounds that lack target-specificity or membrane permeability should decrease the
cost and time required to obtain promising lead compounds for further development.
Having demonstrated the TAFiS methodology using a fungal protein with a highly
favorable profile for drug discovery, i.e. a small, globular, soluble protein with a well
defined active site, we next sought to determine if the method could provide a viable
approach to developing HTP screening assays for a less well characterized target protein
that was poorly suited to traditional approaches.

Chapter 4: Identification of Inhibitors of Fungal Fatty Acid Biosynthesis
One of the biggest advantages of using TAFiS and other TBWCS methodologies
is their potential application to traditionally challenging drug targets, such as those that
are membrane-bound, to large to purify, or not amenable to biochemical HTP assays.
TAFiS was applied to FAS and Ole1p, both of which are previously validated antifungal
targets in the fungal fatty acid biosynthetic pathway and are not well suited for traditional
approaches to chemical screens as either too large to purify or integrated into membranes,
respectively. Both expression pools reliably and reproducibly identified the respective
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inhibitor in TAFiS assay dose-responses, and Z`-factors were sufficient for HTP
screening applications. Subsequently, we screened a total of 41,261 compounds with each
expression pool to identify novel inhibitors of these two targets.
Primary hits were identified for both targets, but only hits from the OLE1 screen
had confirmed activity in subsequent dose-response TAFiS assays. The lack of confirmed
hits for FAS is likely due to the limited-expression differential between the strains we
constructed, as determined by RTqPCR, and susceptibility differential, determined by
dose-responses to CRL a known FAS inhibitor, of the FAS expression pool. However,
the Ole1p screening identified a family of small molecules with a novel hydrazine core
scaffold. Therefore, we have demonstrated that TAFiS can rapidly identify compounds
that interact with traditionally challenging targets, such as Ole1p. TAFiS’s ability to
identify novel inhibitors of targets that were not suited to conventional approaches should
increase the range of proteins that are subject to HTP screening for antifungal discovery.
Next, we determined if the TAFiS assay could be used to explore structureactivity relationships (SAR), and to ensure that analogs retained the ability to interact
with the original molecular target. Therefore, we chose to identify the structural elements
of ECC190, a 1,2,4 triazolidine scaffold previously identified to inhibit Ole1p, and the
two most potent hits from the Ole1p screens, both of which contained the hydrazine core.
We observed that ECC190 had the potential to degrade into 4-phenyl-2-[2-(propan-2ylidene)hydrazinyl]-1,3-thiazole that was nearly identical to a series of potent antifungal
compounds with an unknown molecular target reported by Carradori et al. [90]. An
ECC190 analog was synthesized, and the degradation was confirmed by NMR. We
further identified structural elements of the breakdown-product that are essential for
ECC190 activity against the desaturase using dose-response TAFiS assays to confirm that
the analogs inhibited Ole1p. We showed that modification of the thiazole linker, nearly
all substitutions to the aromatic ring, or extensive modifications to the R groups
decreased the potency, without affecting the scaffold’s ability to inhibit the desaturase. In
addition, hydrophilic additions to the R groups and the loss of aromaticity in the ring
eliminated the scaffold’s ability to induce a population shift in the Ole1p expression pool,
and therefore inhibit the desaturase. This suggests that the inhibitor requires a
hydrophobic nature, possibly binding in a hydrophobic pocket and that the aromatic ring
probably interacts with other aromatic structures in this binding pocket. In addition, we
generated analogs of the hydrazine scaffold we identified represented by FAI354 and
FAI409. Each analog was tested for antifungal against a wild-type C. albicans strains and
against the Ole1p TAFiS assay to ensure that analogs inhibited Ole1p. We found that the
central hydrazine core was essential for the hydrazine-based scaffold to induce the
population shift in the Ole1p expression pool, and therefore inhibit the enzyme.
Furthermore, we found that substitutions on the aromatic ring had small reductions in the
potency of the scaffold. Both the 1,2,4 thiazolidine and hydrazine scaffold SAR studies
demonstrate that TAFiS can be used as a tool to ensure that the analogs retain their ontarget activity against the original molecular target.
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Conclusions
Overall, we have validated a novel and highly sensitive target-based whole-cell
screen to detect interactions between small molecules and a specific target protein within
whole cells. This approach rapidly eliminates compounds that lack the ability to cross the
plasma membrane or target specificity and can be applied to traditionally challenging
targets such as Ole1p, a fungal FA desaturase. Furthermore, we have demonstrated that
TAFiS can be used as a tool in SAR studies to ensure that the analogs retain the ability to
interact with the original molecular target, while still impacting the growth of the whole
cell. Due to the potential for TAFiS to be applied to any target in any genetically tractable
microbe, we fully expect the development of similar methodologies in other pathogenic
fungal species and bacterial species for the identification of promising lead antifungal or
antibacterial compounds. Due to the ease of recombinant protein expression, TAFiS
could be utilized in the model organism Saccharomyces cerevisiae to express targets
from nonculturable microbes, or even disease-relevant human proteins for chemical
screening. This novel methodology for chemical screening should decrease the
inefficiencies and timeline to discover promising lead compounds.
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